drug_name,atc,summary,Persistence,Bioaccumulation,Toxicity,Risk
abacavir,J05AF06,SummaryThis summary information comes from Fass, Abacavir is potentially persistent, Abacavir has low potential for bioaccumulation, Abacavir has low chronic toxicity, The use of abacavir (sales data Sweden 2019) has been considered to result in insignificant environmental risk
abatacept,L04AA24,SummaryHazard - , - , - , - , Exempt
abciximab,B01AC13,SummaryHazard - , - , - , - , Exempt
abiraterone,L02BX03,SummaryHazard 6 , 0 , 3 , 3 , High 
acamprosate,N07BB03,Summary, Acamprosate is potentially persistent, Acamprosate has low potential for bioaccumulation," Acamprosate has low acute toxicity. See comment about this under ""Detailed information""", The use of acamprosate (sales data Sweden 2018) has been considered to result in insignificant environmental risk. This summary information comes from Fass
acarbose,A10BF01,SummaryHazard 3* , 3 , 0 , 0* , Cannot be excluded 
acetazolamide,S01EC01,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
acetylcysteine,R05CB01,SummaryHazard - , - , 0 , - , Cannot be excluded 
acetylsalicylicacid,N02BA01,SummaryThis summary information comes from Fass (Bayer), Acetylsalicylic acid is degraded in the environment, Acetylsalicylic acid has low potential for bioaccumulation, Acetylsalicylic acid has moderate chronic toxicity, The use of acetylsalicylic acid (sales data Sweden 2018) has been considered to result in low environmental risk
aciclovir,D06BB03,Summary, Aciclovir is potentially persistent, Aciclovir has low potential for bioaccumulation, Aciclovir has low chronic toxicity, The use of aciclovir (sales data Sweden 2019) has been considered to result in insignificant environmental risk. This summary information comes from Fass for Geavir (aciclovir)
acitretin,D05BB02,SummaryThis summary information comes from Fass, No data, No data, No data, Cannot be excluded since no ecotoxicity data are available. Environmental data are missing on fass.se (2020-12-07). It is voluntary for manufacturers to provide information about environmental impact on fass.se
adalimumab,L04AB04,"SummaryRisk. Use of amino acids, proteins and peptides is not considered to cause any environmental impact. This summary information comes from Fass and corresponding information can be found in assessment reports.",see summary,see summary,see summary,see summary
adapalene,D10AD03,Summary," It cannot be excluded that adapalene is persistent, due to the lack of data"," It cannot be excluded that adapalene bioaccumulates, due to the lack of data"," It cannot be excluded that adapalene is toxic, due to the lack of data", 
afatinib,L01XE13,SummaryHazard 2* , 0 , 0 , 2* , Insignificant
aflibercept,S01LA05,SummaryHazard - , - , - , - , See below
alemtuzumab,L04AA34,SummaryHazard - , - , - , - , See below
alendronicacid,M05BA04,Summary, Alendronic acid is slowly degraded in the environment, Alendronic acid has low potential for bioaccumulation, Alendronic acid has low chronic toxicity, The use of alendronic acid (sales data Sweden 2019) has been considered to result in insignificant environmental risk.This summary information comes from Fass
alfacalcidol,A11CC03,SummaryHazard - , - , - , - , Exempt According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHM
alfentanil,N01AH02,SummaryEnvironmental information for the substance is not available on fass.se (2021-12-08). It is voluntary for manufacturers to publish environmental impact information on Fass.se.,see summary,see summary,see summary,see summary
alfuzosin,G04CA01,SummaryThis summary information comes from Fass," It cannot be excluded that alfuzosin is persistent, due to the lack of data. Alfuzosin has been found in the Swedish aquatic environment, see further the references", Alfuzosin has low potential for bioaccumulation, Alfuzosin has moderate acute toxicity, The use of alfuzosin (sales data Sweden 2018) has been considered to result in insignificant environmental risk
alginicacid,A02BX13,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
alimemazine,R06AD01,SummaryHazard 9* , 3 , 3* , 3* , See below
allopurinol,M04AA01,Summary, Allopurinol is potentially persistent, Allopurinol has low potential for bioaccumulation, Allopurinol has very high acute toxicity, The use of allopurinol (sales data Sweden 2021) has been considered to result in moderate environmental risk. This summary information comes from Fass
almotriptan,N02CC05,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
alprazolam,N05BA12,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
alprostadil,G04BE01,Summary," It cannot be excluded that alprostadil is persistent, due to the lack of data", Alprostadil has low potential for bioaccumulation," It cannot be excluded that alprostadil is toxic, due to the lack of data", 
alteplase,B01AD02,"SummaryAlteplase is a glucoprotein. Risk. The use of amino acids, proteins and peptides is not considered to have any environmental impact. This summary information comes from Fass.",see summary,see summary,see summary,see summary
ambenonium,N07AA30,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
ambroxol,R05CB06,SummaryHazard 5 , 3 , 0 , 2 , Insignificant 
amikacin,J01GB06,Summary, Amikacin is very persistent (vP), Amikacin has low potential for bioaccumulation, Amikacin has very high chronic toxicity," """
aminolevulinicacid,L01XD04,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
amiodarone,C01BD01,Summary, Amiodarone is potentially persistent, Amiodarone has high potential for bioaccumulation, Amiodarone has high chronic toxicity, The use of amiodarone (sales data Sweden 2021) has been considered to result in insignificant environmental risk. This summary information comes from Fass
amitriptyline,N06AA09,Summary," It cannot be excluded that amitriptyline is persistent, due to the lack of data", Amitriptyline has a high potential to bioaccumulate," It cannot be excluded that amitriptyline is toxic, due to the lack of data", 
amlodipine,C08CA01,"SummaryThis summary information on persistence, bioaccumulation and toxicity comes from Fass. The risk comes from the report of Goodpoint. ", Amlodipine is degraded in the environment, Amlodipine has low potential for bioaccumulation, Amlodipine has high chronic toxicity, See the report from Goodpoint below
amorolfine,D01AE16,Summary," It cannot be excluded that amorolfine is persistent, due to the lack of data"," It cannot be excluded that amorolfine bioaccumulates, due to the lack of data"," It cannot be excluded that amorolfine is toxic, due to the lack of data", 
amoxicillin,J01CA04,Summary, Amoxicillin is potentially persistent, Amoxicillin has low potential for bioaccumulation, Amoxicillin has a very high chronic toxicity, 
amphotericinb,J02AA01,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
ampicillin,J01CA01,Summary," It cannot be excluded that ampicillin is persistent, due to the lack of data"," It cannot be excluded that ampicillin bioaccumulates, due to the lack of data"," It cannot be excluded that ampicillin is toxic, due to the lack of data", 
amsacrine,L01XX01,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
anagrelide,L01XX35,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
anakinra,L04AC03,SummaryHazard - , - , - , - , Exempt
anastrozole,L02BG03,Summary," It cannot be excluded that anastrozole is persistent, due to the lack of data"," It cannot be excluded that anastrozole bioaccumulates, due to the lack of data"," It cannot be excluded that anastrozole is toxic, due to the lack of data", 
apixaban,B01AF02,"SummaryThis summary information on persistence, bioaccumulation and toxicity comes from the assessment report for Eliquis (apixaban) June 26, 2014 and Fass. The risk comes from Fass. ", Apixaban is degraded slowly in the environment, Apixaban has low potential for bioaccumulation, Apixaban has low chronic toxicity, The use of apixaban (sales data Sweden 2018) has been considered to result in insignificant environmental risk
apraclonidine,S01EA03,SummaryHazard - , - , 0 , - , Cannot be excluded 
aprepitant,A04AD12,SummaryHazard 6* , 3 , 0 , 3* , Insignificant 
aprotinin,B02AB01,SummaryHazard - , - , - , - ," ExemptFass environmental informationFass environmental information for Artiss (among others aprotinin, bovint, syntetiskt) from "
aripiprazole,N05AX12,SummaryHazard 9* , 3 , 3* , 3 ," Insignificant No measurements of aripripazole have been reported from wastewater or the external environment, either in Sweden or abroad. However, the reason may be that no one has specifically searched for the substance. Aripiprazole is slowly degraded in the environment.In the literature there are contradictory fat solubility data for alimemazine reported. However, several independent sources report an estimated fat solubility (log"
atazanavir,J05AE08,SummaryHazard 5 , 3 , 0 , 2 , Insignificant 
atenolol,C07AB03,SummaryHazard - , - , 0 , - , See below Underlying data for 
atomoxetine,N06BA09,SummaryHazard 6 , 3 , 0 , 3 , Insignificant 
atorvastatin,C10AA05,"SummaryThis summary information on persistence, bioaccumulation and toxicity comes from previous environmental information on Fass.se. Environmental information is missing on fass.se for atorvastatin (2021-06-11). It is voluntary for manufacturers to provide information on environmental impact on fass.se. The risk is from the report by Goodpoint. ", Atorvastatin is slowly degraded in the environment, Atorvastatin does not have the potential for bioaccumulation in aquatic organisms, Atorvastatin has moderate acute toxicity, See the report by Goodpoint below
atosiban,G02CX01,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
atovaquone,P01AX06,SummaryHazard 9* , 3* , 3 , 3* , Cannot be excluded 
atracurium,M03AC04,SummaryEnvironmental information is missing on fass.se for atracurium (2022-01-13). It is voluntary for manufacturers to provide information on environmental impact on fass.se. ," It cannot be excluded that atracurium is persistent, due to the lack of data"," It cannot be excluded that atracurium bioaccumulates, due to the lack of data"," It cannot be excluded that atracurium is toxic, due to the lack of data", 
atropine,S01FA01,SummaryHazard - , - , 0 , - , Cannot be excluded 
auranofin,M01CB03,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
azathioprine,L04AX01,SummaryHazard - , - , - , - , Cannot be excluded 
azelaicacid,D10AX03,Summary," It cannot be excluded that azelaic acid is persistent, due to the lack of data"," It cannot be excluded that azelaic acid bioaccumulates, due to the lack of data"," It cannot be excluded that azelaic acid is toxic, due to the lack of data", For azelaic acid there is nothing that indicates an environmental hazard. Environmental information is missing on fass.se for azelaic acid (2022-06-30). It is voluntary for manufacturers to provide information on environmental impact on fass.se
azelastine,R01AC03,SummaryHazard 6* , 3 , 0 , 3* , Insignificant 
azithromycin,J01FA10,"SummaryEnvironmental information for azithromycin is missing on fass.se (2021-08-16). It is voluntary for manufacturers to provide information about environmental impact on fass.se. This summary information on persistence, bioaccumulation and toxicity is based on previous environmental information in Fass from 2011. For risk, see the environmental assessment from Goodpoint. ", Azithromycin is slowly degraded in the environment, Azithromycin has no potential to bioaccumulate, Azithromycin has a very high acute toxicity, See the environmental assessment from Goodpoint below. Suggestions on how to reduce emissions of azithromycin
aztreonam,J01DF01,SummaryHazard 6* , 3* , 0 , 3 , Cannot be excluded 
baclofen,M03BX01,SummaryHazard 3* , 3 , 0 , 0* , Cannot be excluded 
baricitinib,L04AA37,SummaryHazard 4 P 3 B 0 T 1 Risk InsignificantThis summary information comes from assessment report for Olumiant (baricitinib)," Baricitinib is potentially peristent according to expert (Researcher at the Department of Environmental Science and Analytical Chemistry (ACES), Stockholm University 2020-05-06)", Baricitinib has low potential for bioaccumulation, Baricitinib has moderate chronic toxicity, Expected use of baricitinib from a European perspective gives the risk insignificant
basiliximab,L04AC02,SummaryHazard - , - , - , - , Exempt
bazedoxifene,G03XC02,SummaryThis summary information comes from the assessment report from 2014. , Bazedoxifene is not persistent, Bazedoxifene has low potential for bioaccumulation, Bazedoxifene has very high chronic toxicity," ""The data provided by the Applicant do allow concluding that bazedoxifene is unlikely to present a risk to the environmental compartments surface water, groundwater and sediment as well as wastewater microorganisms. No final conclusion is possible on the potential risk of bazedoxifene to the terrestrial environment. [...] The Environmental "
bedaquiline,J04AK05,SummaryHazard 9 , 3 , 3 , 3 , See below 
benzoylperoxide,D10AE01,Summary, Benzoyl peroxide is degraded in the environment, Benzoyl peroxide has low potential for bioaccumulation, Benzoyl peroxide has very high acute toxicity, The use of Benzoyl peroxide (sales data Sweden 2019) has been considered to result in moderate environmental risk. This summary information comes from Fass
benzylpenicillin,J01CE01,SummaryHazard 6 , 3 , 0 , 3 , Cannot be excluded 
betamethasone,D07AC01,SummaryThis summary information comes from Fass. , Betamethasone is potentially persistent, Betamethasone has low potential for bioaccumulation, Betamethasone has very high chronic toxicity, The use of betamethasone (sales data Sweden 2018) has been considered to result in high environmental risk
betaxolol,S01ED02,SummaryHazard - , - , 0 , - , Cannot be excluded 
bevacizumab,L01XC07,SummaryHazard - , - , - , - , Exempt
bexarotene,L01XX25,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
bezafibrate,C10AB02,SummaryThis summary information on toxicity and persistence is based on previous environmental information on fass.se for Bezalip from Actavis (downloaded 2011-04-14). Bioaccumulation and risk come from the report from Goodpoint. , Bezafibrate is slowly degraded in the environment," All fibrates examined are fat soluble with a log P between 3.9 and 5.2. This is likely low enough for some to be found in soluble form in surface water, but at the same time high enough to bioconcentrate effectively", Bezafibrate has high acute toxicity," The use of bezafibrate, fenofibrate and gemfibrozil is not considered to pose an environmental risk"
bibrocathol,S01AX05,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
bicalutamide,L02BB03,SummaryHazard 5 , 3 , 0 , 2 , Insignificant 
bifonazole,D01AC10,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
bimatoprost,S01EE03,Summary, No data, No data, No data, Cannot be excluded. Environmental information is missing on fass.se for bimatoprost (2020-09-07). It is voluntary for manufacturers to provide information on environmental impact on fass.se
biperiden,N04AA02,SummaryHazard - , - , - , 2* , Cannot be excluded 
bisacodyl,A06AB02,SummaryHazard 5 , 3 , 0 , 2 , Insignificant 
bisoprolol,C07AB07,SummaryThis summary information comes from Fass. , Bisoprolol is degraded in the environment. , Bisoprolol has low potential for bioaccumulation, Bisoprolol has low chronic toxicity, The use of bisoprolol (sales data Sweden 2018) has been considered to result in insignificant environmental risk
bleomycin,L01DC01,SummaryHazard - , - , - , - , Cannot be excluded Manufacturer has on fass.se stated that that data about the environmental impact is missing for the substance so that the environmental risk cannot be calculated. It is voluntary for manufacturers to provide information on the environmental impact on fass.se
blinatumomab,L01XC19,SummaryHazard - , - , - , - , Exempt
boceprevir,J05AE12,SummaryHazard 2* , 0 , 0 , 2* , Insignificant 
bortezomib,L01XX32,SummaryHazard - , - , - , 3 , Insignificant 
bosentan,C02KX01,SummaryHazard - , - , 0 , - , Cannot be excluded 
brentuximabvedotin,L01XC12,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
brimonidine,S01EA05,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
brinzolamide,S01EC04,SummaryHazard - , - , 0 , - , Cannot be excluded 
bromhexine,R05CB02,SummaryHazard 6 , 3 , 0 , 3 , Cannot be excluded
bromocriptine,N04BC01,Summary," It cannot be excluded that bromocriptine is persistent, due to the lack of data", Bromocriptine has low potential for bioaccumulation," It cannot be excluded that bromocriptine is toxic, due to the lack of data", 
budesonide,A07EA06,"SummaryThe data on persistence, bioaccumulation and toxicity come from the assessment reports from 2020. The risk comes from the report of Goodpoint. ", Budesonide is likely non-persistent, Budesonide has low potential for bioaccumulation, Budesonide has high chronic toxicity, The use of budesonide poses an environmental risk
bumetanide,C03CA02,SummaryHazard 4* , 3* , 0 , 1* , Cannot be excluded No experimental values have been found regarding the ecotoxicity of 
bupivacaine,N01BB01,SummaryHazard 5* , 3* , 0 , 2* , Cannot be excluded
buprenorphine,N02AE01,Summary, Buprenorphine is slowly degraded in the environment, Buprenorphine has low potential for bioaccumulation, Buprenorphine has very high chronic toxicity," From a European perspective, the use of buprenorphine has been considered to result in insignificant environmental risk. This summary information comes from the assessment report for Zubsolv (buprenorphine, naloxone) 2017. The data for calculating risk in assessment reports for a medicinal product do not necessarily represent the total emission of all products with the same active substance during use. Buprenorphine is used in medical patches which may contain significant drug residues after use. Even used patches should be submitted to the pharmacy for destruction"
bupropion,N06AX12,Summary, Bupropion is potentially persistent, Bupropion has low potential for bioaccumulation, Bupropion has very high chronic toxicity," The use of bupropion (sales data Sweden 2021) has been considered to result in insignificant environmental risk. See comment under the heading ""Detailed information"" if using PNEC value for bupropion from the assessment report of Mysimba (naltrexone/bupropion).This summary information comes from Fass except from the toxicity information that comes from the assessment report. Data for bioaccumulation is also supported by information in the assessment report"
buserelin,L02AE01,SummaryHazard - , - , - , - , See below
buspirone,N05BE01,SummaryHazard 6* , 3 , 0 , 3* , Cannot be excluded
busulfan,L01AB01,SummaryHazard 2* , 0 , 0 , 2* , Cannot be excluded
butylscopolamine,A03BB01,SummaryHazard 4 , 3 , 0 , 1 , Insignificant
cabazitaxel,L01CD04,SummaryHazard 6 , 3 , 0 , 3 , Insignificant 
cabergoline,G02CB03,Summary," It cannot be excluded that cabergoline is persistent, due to the lack of data"," It cannot be excluded that cabergoline bioaccumulates, due to the lack of data"," It cannot be excluded that cabergoline is toxic, due to the lack of data", 
caffeine,N06BC01,Summary," The potential for persistence of caffeine cannot be excluded, due to lack of data", Caffeine has low potential for bioaccumulation, Caffeine has moderate acute toxicity, The use of caffeine (sales data Sweden 2017) has been considered to result in insignificant environmental risk. This summary information comes from Fass
calcipotriol,D05AX02,Summary, Calcipotriol is potentially persistent, Calcipotriol has high potential for bioaccumulation," It cannot be excluded that calcipotriol is toxic, due to the lack of data", 
calcitriol,A11CC04,SummaryHazard - , - , - , - , Exempt According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHM
calciumcarbonate,A12AA04,SummaryThis summary information comes from Fass. The use of electrolytes is not considered to have any environmental impact.,see summary,see summary,see summary,see summary
calciumchloride,A12AA07,SummaryHazard - , - , - , - , Exempt According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHM
calciumfolinate,V03AF03,SummaryHazard - , - , - , - , Exempt According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHM
canagliflozin,A10BX11,SummaryHazard 5 , 3 , 0 , 2 , Insignificant 
canakinumab,L04AC08,SummaryHazard - , - , - , - , Exempt
candesartan,C09CA06,"SummaryThis summary information on persistence, bioaccumulation and toxicity comes from Fass. The risk is from the report by Goodpoint. ", Candesartan is persistent, Candesartan has low potential for bioaccumulation, Candesartan has moderate chronic toxicity, See the report by Goodpoint below
capecitabine,L01BC06,No recorded data,see summary,see summary,see summary,see summary
captopril,C09AA01,SummaryHazard - , - , - , - , Low
carbachol,S01EB02,SummaryHazard - , - , 0 , - , Cannot be excluded
carbamazepine,N03AF01,Summary," Carbamazepine is persistent. See comment on ""potentially persistence"" that is written in Fass under the heading ""Detailed information"" below", Carbamazepine has low potential for bioaccumulation, Carbamazepine has high chronic toxicity," The use of carbamazepine (sales data Sweden 2018) has been considered to result in low environmental risk.This summary information comes from Fass. The information about persistence, bioaccumulation and risk is also supported by the report from Goodpoint"
carbetocin,H01BB03,SummaryHazard - , - , - , - , Se below
carboplatin,L01XA02,SummaryHazard 4* , 3* , 0 , 1* , Cannot be excluded
carboprost,G02AD04,Summary," It cannot be excluded that carboprost is persistent, due to the lack of data"," It cannot be excluded that carboprost bioaccumulates, due to the lack of data"," It cannot be excluded that carboprost is toxic, due to the lack of data", 
carfilzomib,L01XX45,SummaryHazard - , - , 3 , - , Cannot be excluded
carvedilol,C07AG02,Summary," It cannot be excluded that carvedilol is persistent, due to the lack of data"," It cannot be excluded that carvedilol bioaccumulates, due to the lack of data"," It cannot be excluded that carvedilol is toxic, due to the lack of data", 
caspofungin,J02AX04,SummaryHazard 6 , 3 , 0 , 3 , Insignificant
cefadroxil,J01DB05,Summary," It cannot be excluded that cefadroxil is persistent, due to the lack of data"," It cannot be excluded that cefadroxil bioaccumulates, due to the lack of data"," It cannot be excluded that cefadroxil is toxic, due to the lack of data", 
cefalexin,J01DB01,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
cefepime,J01DE01,SummaryHazard 3* , 3 , 0 , 0* , Insignificant Since 2012-03-31 there is no registered drug containing cefepime in the Swedish market 
cefotaxime,J01DD01,SummaryHazard - , - , 0 , - , Cannot be excluded Underlying information for 
ceftazidime,J01DD02,SummaryHazard 5 , 3 , 0 , 2 , Insignificant 
ceftriaxone,J01DD04,SummaryHazard 6* , 3 , 0 , 3* , Cannot be excluded 
cefuroxime,S01AA27,SummaryHazard 6* , 3 , 0 , 3* , See below 
celecoxib,M01AH01,Summary," It cannot be excluded that celecoxib is persistent, due to the lack of data"," It cannot be excluded that celecoxib bioaccumulates, due to the lack of data"," It cannot be excluded that celecoxib is toxic, due to the lack of data", The environmental risk is not considered to be that great from a Swedish perspective. Information about the risk comes from the report by Goodpoint 2019. Environmental information is missing on fass.se (2023-03-16). It is voluntary for manufacturers to provide information about environmental impact on fass.se
certolizumabpegol,L04AB05,SummaryHazard - , - , - , - , See below
cetirizine,R06AE07,Summary," It cannot be excluded that cetirizine is persistent, due to the lack of data", Cetirizine has low potential for bioaccumulation," It cannot be excluded that cetirizine is toxic, due to the lack of data", The use of cetirizine in Sweden has been considered to result in low environmental risk. The data for bioaccumulation is based on previous environmental information. Environmental information is missing on fass.se (2022-06-30). It is voluntary for manufacturers to provide information about environmental impact on fass.se. 
cetrorelix,H01CC02,SummaryHazard - , - , - , - , Exempt
cetuximab,L01XC06,SummaryHazard - , - , - , - , Exempt
chlorambucil,L01AA02,SummaryHazard 2* , 0 , 0 , 2* , Cannot be excluded
chloramphenicol,S01AA01,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
chlorhexidine,R02AA05,SummaryHazard 6* , 3* , 0 , 3* , Cannot be excluded
chlorprothixene,N05AF03,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
ciclesonide,R03BA08,SummaryThe data on hazard and risk are based on previous environmental information on fass.se. Environmental information is missing (2022-01-17). It is voluntary for manufacturers to provide information about environmental impact on fass.se. , Ciclesonide is slowly degraded in the environment, Ciclesonide has low potential for bioaccumulation," It cannot be excluded that ciclesonide is toxic, due to the lack of data", 
cilazapril,C09AA08,SummaryHazard 4 , 3 , 0 , 1 , Insignificant
cimetidine,A02BA01,SummaryHazard 3 , 3 , 0 , 0 , Insignificant
cinacalcet,H05BX01,SummaryHazard 5 , 3 , 0 , 2 , Insignificant 
ciprofloxacin,S03AA07,Summary, Ciprofloxacin is potentially persistent, Ciprofloxacin has low potential for bioaccumulationn, Ciprofloxacin has a very high chronic toxicity, The use of ciprofloxacin (sales data Sweden 2019) has been judged to entail a risk high of environmental impact.This summary information comes from Fass. The risk is also confirmed by the report from Goodpoint.Suggestions on how to reduce emissions of ciprofloxacin
cisatracurium,M03AC11,SummaryHazard 2* , 0 , 0 , 2* , Cannot be excluded 
cisplatin,L01XA01,SummaryHazard 6* , 3* , 0 , 3 , Cannot be excluded
citalopram,N06AB04,"SummaryEnvironmental information for citalopram is missing on fass.se (2020-10-12). It is voluntary for manufacturers to provide information about environmental impact on fass.se. This summary information on persistence, bioaccumulation and toxicity is based on previous environmental information in Fass from 2018. For risk, see the environmental assessments from Goodpoint. "," The potential for persistence of citalopram cannot be excluded, due to lack of data", Citalopram has low potential for bioaccumulation, Citalopram has very high acute toxicity," See the environmental assessments from Goodpoint below. Citalopram is a racemate of which one of the enantiomers, escitalopram (S-form), has the pharmacological effect. Therefore, see also the information about escitalopram. Suggestions on how to reduce emissions of citalopram and escitalopram"
cladribine,L01BB04,SummaryHazard 5* , 3* , 0 , 2 , Insignificant
clarithromycin,J01FA09,"SummaryThe information on persistence, bioaccumulation and toxicity in this summary information is based on previous environmental information on fass.se. Environmental information is missing (2021-08-16). It is voluntary for manufacturers to provide information on environmental impact on fass.se. The risk comes from the report by Goodpoint. ", Clarithromycin is potentially persistent, Clarithromycin has low potential for bioaccumulation, Clarithromycin has very high acute toxicity, See the report by Goodpoint. Suggestions on how to reduce the emissions of clarithromycin
clemastine,R06AA04,SummaryHazard - , - , 3 , - , See below Underlying information för 
clindamycin,D10AF01,Summary," It cannot be excluded that clindamycin is persistent, due to the lack of data", Clindamycin has low a low potential for bioaccumulation," It cannot be excluded that clindamycin is toxic, due to the lack of data", 
clobetasone,D07AB01,Summary, Clobetasone is potentially persistent, Clobetasone has low potential for bioaccumulation, Clobetasone has very hig acute toxicity, 
clodronicacid,M05BA02,SummaryHazard 4 , 3 , 0 , 1 , Insignificant
clofarabine,L01BB06,SummaryHazard - , - , - , - , Cannot be excluded
clomethiazole,N05CM02,SummaryHazard 4 , 3 , 0 , 1 , Insignificant
clomipramine,N06AA04,SummaryHazard 6* , 3 , 0 , 3* , See below
clonazepam,N03AE01,SummaryHazard 4* , 3 , 0 , 1* , Insignificant 
clonidine,C02AC01,SummaryHazard 6* , 3 , 0 , 3* , Cannot be excluded
clopidogrel,B01AC04,Summary, Clopidogrel is degraded in the environment, Clopidgrel has low potential for bioaccumulation, Clopidgrel has moderate chronic toxicity, The use of clopidogrel (sales data Sweden 2019) has been considered to result in insignificant environmental risk. This summary information about hazard comes from fass.se and the assessment report for Plavix (clopidogrel) and Iscover (clopidogrel). The risk comes from fass.se
clotrimazole,D01AC01,SummaryThe data on hazard and risk are based on previous environmental information on fass.se. Environmental information is missing (2021-09-10). It is voluntary for manufacturers to provide information about environmental impact on fass.se. Clotrimazole is monitored within the framework of EU water legislation. , Clotrimazole is potentially persistent, Clotrimazole has high potential for bioaccumulation, Clotrimazole has high chronic toxicity, The use of clotrimazole (sales data Sweden 2011) has been considered to result in insignificant environmental risk
cloxacillin,J01CF02,SummaryHazard 6* , 3 , 0 , 3* , Cannot be excluded
clozapine,N05AH02,SummaryHazard 9 , 3 , 3 , 3 , Low 
codeine,R05DA04,SummaryHazard - , - , 0 , - , See below Underlying data for 
colchicine,M04AC01,Summary," It cannot be excluded that colchicine is persistent, due to the lack of data"," It cannot be excluded that colchicine bioaccumulates, due to the lack of data"," It cannot be excluded that colchicine is toxic, due to the lack of data", 
colecalciferol,A11CC05,"SummaryThis summary information comes from Fass (Baxter, Meda, Organon Sweden, Recip AB and Takeda Pharma).The use of vitamins is not considered to have any environmental impact.",see summary,see summary,see summary,see summary
colestipol,C10AC02,SummaryHazard - , - , - , - , Cannot be excluded 
cyanocobalamin,B03BA01,"SummaryThis summary information comes from Fass (Baxter, Fresenius Kabi and Pfizer). Risk: The use of vitamins is not considered to have any environmental impact.",see summary,see summary,see summary,see summary
cyclopentolate,S01FA04,SummaryHazard - , - , 0 , - , Cannot be excluded
cyclophosphamide,L01AA01,SummaryHazard 5 , 3 , 0 , 2 , Cannot be excluded
cyproheptadine,R06AX02,SummaryHazard 9* , 3 , 3 , 3* , Cannot be excluded 
cyproterone,G03HA01,SummaryHazard 6* , 3 , 0 , 3* , Cannot be excluded 
cytarabine,L01BC01,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
dabigatranetexilate,B01AE07,Summary, Dabigatran is “degraded in the environment, Dabigatran has low potential for bioaccumulation, Dabigatran has moderate chronic toxicity, The use of dabigatran (sales data Sweden 2019) has been considered to result in insignificant environmental risk. This summary information about persistence and bioaccumulation comes from assessment report and Fass. The information about toxicity and risk comes from Fass
dacarbazine,L01AX04,SummaryHazard - , - , - , - , Cannot be excluded
daclizumab,L04AC01,SummaryHazard - , - , - , - , Exempt Medicinal products containing daclizumab are no longer authorised in the European union. 
dalteparin,B01AB04,"SummaryThe use of amino acids, proteins and peptides is not considered to have any environmental impact. This summary information comes from Fass.",see summary,see summary,see summary,see summary
danaparoid,B01AB09,SummaryHazard - , - , - , - , Exempt 
dapagliflozin,A10BX09,SummaryEnvironmental information is missing on fass.se (2021-09-29). It is voluntary for manufacturers to provide information about environmental impact on fass.se. This summary information on bioaccumulation and toxicity comes from the assessment report and previous environmental information on fass.se. The information about persistence comes from the assessment report. The risk comes from Fass. , Dapagliflozin slowly degrades in the environment, Dapagliflozin has low potential for bioaccumulation, Dapagliflozin has moderate chronic toxicity, The use of dapagliflozin (sales data Sweden 2016) has been judged to entail a insignificant risk of environmental impact
darbepoetinalfa,B03XA02,SummaryHazard - , - , - , - , Exempt 
darifenacin,G04BD10,SummaryHazard 6 , 3 , 0 , 3 , Insignificant 
darunavir,J05AE10,SummaryHazard 5* , 3 , 0 , 2* , Insignificant 
dasatinib,L01XE06,SummaryHazard 5 , 3 , 0 , 2 , Low
daunorubicin,L01DB02,SummaryHazard - , - , - , - , Cannot be excluded
deferasirox,V03AC03,SummaryHazard 6 , 3 , 0 , 3 , Insignificant 
deferoxamine,V03AC01,SummaryHazard 1* , 0 , 0 , 1* , Insignificant 
denosumab,M05BX04,"SummaryRisk. The use of amino acids, proteins and peptides is not considered to have any environmental impact. This information comes from Fass.",see summary,see summary,see summary,see summary
dequalinium,R02AA02,SummaryEnvironmental information is missing on fass.se (2022-04-11). It is voluntary for manufacturers to provide information about environmental impact on fass.se.,see summary,see summary,see summary,see summary
desflurane,N01AB07,SummaryHazard - , - , - , - , Cannot be excluded
desloratadine,R06AX27,"SummaryThis summary information on persistence, bioaccumulation and toxicity is based on previous environmental information on fass.se. Environmental information is missing (2021-06-28). It is voluntary for manufacturers to provide information about environmental impact on fass.se. The risk comes from the report of Goodpoint 2019. ", Desloratadine is potentially persistent, Desloratadine has low potential for bioaccumulation, Desloratadine has moderate chronic toxicity, The use of desloratadine in Sweden has been considered to result in low environmental risk (2019)
desmopressin,H01BA02,"SummaryDesmopressin is a peptide. Risk. The use of amino acids, proteins and peptides is not considered to have any environmental impact but see below for further information from Ferring. This summary information comes from Fass.",see summary,see summary,see summary,see summary
desogestrel,G03AC09,SummaryDesogestrel is converted in the body into the active metabolite etonogestrel. Environmental data from Fass refer to etonogestrel. This summary information comes from Fass. See also the report from Goodpoint. , Desogestrel is slowly degraded in the environment, Desogestrel has low potential for bioaccumulation, Desogestrel has very high chronic toxicity, The use of desogestrel (sales data Sweden 2018) has been considered to result in moderate environmental risk
dexamethasone,H02AB02,SummaryHazard - , - , 0 , - , Cannot be excluded
dexamfetamine,N06BA02,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se (2018-10-30). It is voluntary for manufacturers to provide information about environmental impact on fass.se
dexrazoxane,V03AF02,SummaryHazard - , - , - , - , Cannot be excluded
diazepam,N05BA01,SummaryThis summary information comes from Fass and the risk from the report from Goodpoint. , No data, No data, No data, See below Suggestions on how to reduce emissions of diazepam
diboterminalfa,M05BC01,SummaryHazard - , - , - , - , Exempt Underlying data for risk is from assessment report
diclofenac,M01AB05,SummaryThis summary information comes from Fass and the risk from the report from Goodpoint. , Diclofenac is slowly degraded in the environment, Diclofenac has low potential for bioaccumulation, Diclofenac has moderate chronic toxicity, See below. Diclofenac is not recommended in the Wise list (a list of recommended pharmaceuticals from the Stockholm Drug and Therapeutics Committee). Suggestions on how to reduce the emissions of diclofenac
dicloxacillin,J01CF01,SummaryHazard - , - , - , - , Cannot be excluded 
didanosine,J05AF02,SummaryHazard 3* , 3 , 0 , 0* , Insignificant 
dienogest,G03DB08,SummaryThis summary information comes from Fass. , Dienogest is persistent, Dienogest has low potential for bioaccumulation, Dienogest has very high acute/chronic toxicity, The use of dienogest (sales data Sweden 2018) has been considered to result in low environmental risk
digoxin,C01AA05,SummaryEnvironmental information is missing for digoxin on fass.se (2022-05-18). It is voluntary for manufacturers to provide information about environmental impact on fass.se.,see summary,see summary,see summary,see summary
dihydrotachysterol,A11CC02,SummaryHazard - , - , - , - , Exempt 
diltiazem,C08DB01,SummaryHazard 4* , 3 , 0 , 1* ," Cannot be excluded In Sweden diltiazem has been found in wild fish, however in concentrations below therapeutic concentrations. Mekanism-based effect data is missing. "
dinoprostone,G02AD02,Summary," It cannot be excluded that dinoprostone is persistent, due to the lack of data"," It cannot be excluded that dinoprostone bioaccumulates, due to the lack of data"," It cannot be excluded that dinoprostone is toxic, due to the lack of data", 
diphenhydramine,D04AA32,SummaryHazard - , - , 0 , - , Cannot be excluded Underlying data for 
dipyridamole,B01AC07,SummaryHazard 5 , 3 , 0 , 2 , Low
disopyramide,C01BA03,SummaryHazard 4* , 3* , 0 , 1* , Cannot be excluded 
disulfiram,N07BB01,Summary," It cannot be excluded that disulfiram is persistent, due to the lack of data", Disulfiram has low potential for bioaccumulation," It cannot be excluded that disulfiram is toxic, due to the lack of data", 
docetaxel,L01CD02,SummaryHazard - , - , 0 , - , Cannot be excluded Underlying data for 
dolutegravir,J05AX12,SummaryHazard 6 , 3 , 0 , 3 , Insignificant 
donepezil,N06DA02,SummaryThis summary information on persistence and toxicity comes from previous environmental information on fass.se (2011-04-29). Information about bioaccumulation and risk comes from the report from Goodpoint. , Donepezil is potentially persistent," With a log P around 4.7 for donepezil, a strong bioconcentration can be expected", Acute toxicity data are available only for crustacean. ,0.0
dopamine,C01CA04,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
dorzolamide,S01EC03,SummaryHazard 3* , 3 , 0 , 0* , Cannot be excluded 
doxorubicin,L01DB01,SummaryHazard - , - , - , 2* , Cannot be excluded 
doxycycline,J01AA02,Summary," It cannot be excluded that doxycycline is persistent, due to the lack of data"," It cannot be excluded that doxycycline bioaccumulates, due to the lack of data"," It cannot be excluded that doxycycline is toxic, due to the lack of data", 
droperidol,N05AD08,Summary," It cannot be excluded that droperidol is persistent, due to the lack of data"," It cannot be excluded that droperidol bioaccumulates, due to the lack of data"," It cannot be excluded that droperidol is toxic, due to the lack of data", 
dulaglutide,A10BX14,"SummaryRisk. The use of amino acids, proteins and peptides is not considered to have any environmental impact. Even though biomolecules, such as vaccines and hormones, are exempted they should still be regarded as biologically active. This summary information comes from Fass.",see summary,see summary,see summary,see summary
duloxetine,N06AX21,Summary, Duloxetine is considered to be slowly degraded in the environment, Duloxetine has low potential for bioaccumulation, Duloxetine has very high chronic toxicity, The use of duloxetine (sales data Sweden 2020) has been considered to result in low environmental risk. This summary information comes from Fass. The environmental impact of duloxetine is poorly studied according to report LS 2016–0634
dutasteride,G04CB02,SummaryHazard 5* , 3 , 0 , 2* , Insignificant 
dydrogesterone,G03DB01,SummaryEnvironmental information is missing on fass.se for dydrogesterone (2021-04-21). It is voluntary for manufacturers to provide information on environmental impact on fass.se.,see summary,see summary,see summary,see summary
ebastine,R06AX22,SummaryHazard - , - , 3 , - , Low Underlying data for 
econazole,G01AF05,Summary," It cannot be excluded that econazole is persistent, due to the lack of data"," It cannot be excluded that econazole bioaccumulates, due to the lack of data", Econazole has very high acute toxicity, The use of econazole (sales data Sweden 2015) has been considered to result in low environmental risk. The data on hazard and risk are based on previous environmental information on fass.se. Environmental information is missing (2022-06-30). It is voluntary for manufacturers to provide information about environmental impact on fass.se
eculizumab,L04AA25,SummaryHazard - , - , - , - , Exempt 
efavirenz,J05AG03,SummaryHazard 6 , 3 , 0 , 3 , Insignificant
eletriptan,N02CC06,SummaryHazard 5* , 3* , 0 , 2* , Cannot be excluded 
emedastine,S01GX06,SummaryThis summary information comes from Fass. ," It cannot be excluded that emedastine is persistent, due to the lack of data", Emedastine has low potential for bioaccumulation," It cannot be excluded that emedastine is toxic, due to the lack of data", 
enalapril,C09AA02,"SummaryThis summary information on persistence, bioaccumulation and toxicity comes from Fass. The information on bioaccumulation and toxicity is confirmed by the report from Goodpoint. Information about the risk comes from the report from Goodpoint. "," It cannot be excluded that enalapril is persistent, due to the lack of data", Enalapril has low potential for bioaccumulation, Enalapril has low acute toxicity, The use of enalapril has been considered to result in low environmental risk
enfuvirtide,J05AX07,SummaryHazard - , - , - , - , See below
enoxaparin,B01AB05,SummaryHazard - , - , - , - , Exempt 
entacapone,N04BX02,SummaryHazard 5* , 3 , 0 , 2* , Low 
entecavir,J05AF10,SummaryHazard 4 , 3 , 0 , 1 , Insignificant
ephedrine,R01AB05,Summary," It cannot be excluded that ephedrine is persistent, due to the lack of data", Ephedrine has low potential for bioaccumulation," It cannot be excluded that ephedrine is toxic, due to the lack of data", 
epinastine,S01GX10,SummaryHazard - , - , - , - , Cannot be excluded 
epinephrine,C01CA24,SummaryThis summary information comes from Fass. ," It cannot be excluded that epinephrine is persistent, since no data are available", Epinephrine has low potential for bioaccumulation, No data, 
epirubicin,L01DB03,SummaryHazard - , - , - , - , Cannot be excluded 
eplerenone,C03DA04,SummaryEnvironmental information is missing on fass.se (2022-04-26). It is voluntary for manufacturers to provide information about environmental impact on fass.se.,see summary,see summary,see summary,see summary
eprosartan,C09CA02,SummaryHazard 3 , 3 , 0 , 0 , See below 
eptifibatide,B01AC16,SummaryHazard - , - , 0 , - , Cannot be excluded 
erlotinib,L01XE03,SummaryHazard 3 , 3 , 0 , 0 , Insignificant
erythromycin,D10AF02,SummaryThis summary information comes from Fass 2015 and the risk is from the report from Goodpoint. , Erythromycin is potentially persistent, Erythromycin has low potential for bioaccumulation," Erythromycin has very high acute toxicity. However, studies on blue-green algae (Cyanophyta) according to CHMP guidelines are lacking", See below. Suggestions on how to reduce the emissions of erythromycin
escitalopram,N06AB10,"SummaryEnvironmental information for escitalopram is missing on fass.se (2020-10-12). It is voluntary for manufacturers to provide information about environmental impact on fass.se. This summary information on persistence, bioaccumulation and toxicity is based on previous environmental information in Fass from 2017. For risk, see the environmental assessments from Goodpoint. ", Escitalopram oxalate is slowly degraded in the environment, Escitalopram oxalate has low potential for bioaccumultaion, Escitalopram has high chronic toxicity," See the environmental assessments from Goodpoint below. Citalopram is a racemate of which one of the enantiomers, escitalopram (S-form), has the pharmacological effect. In assessing the total environmental risk the quantity of sold citalopram should also be taken into account. Suggestions on how to reduce emissions of escitalopram and citalopram"
esmolol,C07AB09,SummaryHazard - , - , - , - , Cannot be excluded 
esomeprazole,A02BC05,"SummaryThis summary information about persistence, bioccumulation and toxicity comes from the assessment report. The risk is supported by all three references. ", Esomeprazole is not persistent, Esomeprazole has low potential for bioaccumulation, Esomeprazole has moderate chronic toxicity, The use of esomeprazole has been considered to result in insignificant environmental risk
estradiol,G03CA03,"SummaryThis summary information on estradiol comes from Fass Novo Nordisk and Fass Bayer (persistence, bioaccumulation), Fass Bayer (toxicity) and the risk from the report Goodpoint. ", Estradiol is slowly degraded in the environment, Estradiol has low potential to bioaccumulate, Estradiol has very high chronic toxicity, See the report from Goodpoint. Suggestions on how to reduce emissions of estradiol
estramustine,L01XX11,SummaryHazard - , - , - , - , Cannot be excluded 
estriol,G03CA04,"SummaryEnvironmental information is missing on fass.se for estriol (2021-04-21). It is voluntary for manufacturers to provide information about environmental impact on fass.se.Pharmaceutial residues in the aquatic environment in SwedenReport Pharmaceutial residues in the Stockholm aquatic environment. Estriol has been measured in treated wastewater at concentrations up to 20 ng/L in Stockholm, Sweden. The reduction rate in the wastewater treatment plants Henriksdal and Bromma is reported to be 98 %.",see summary,see summary,see summary,see summary
etanercept,L04AB01,"SummaryEtanercept is a protein. Risk. Use of amino acids, proteins and peptides is not considered to cause any environmental impact.  This summary information comes from Fass and corresponding information can be found in assessment reports. In the environmental information from Sandoz AS and Pfizer: Even though biomolecules are exempted they should still be regarded as biologically active. ",see summary,see summary,see summary,see summary
ethosuximide,N03AD01,Summary, No data, No data, No data, Cannot be excluded. Environmental information is missing on fass.se for ethosuximide (2020-09-07). It is voluntary for manufacturers to provide information on environmental impact on fass.se
ethylmorphine,R05DA01,SummaryHazard - , - , - , - , Cannot be excluded 
etidronicacid,M05BA01,SummaryHazard 5 , 3 , 0 , 2 , Insignificant
etilefrine,C01CA01,SummaryHazard 8* , 3 , 3* , 2* , Cannot be excluded
etonogestrel,G03AC08,SummaryThis summary information about hazard comes from fass.se. The risk is from the report by Goodpoint. , Etonogestrel is slowly degraded in the environment, Etonogestrel has low potential for bioaccumulation, Etonogestrel has very high chronic toxicity, There is a risk associated with the use of etonogestrel/desogestrel and that these substances appear additive with other androgenic gestagens in the environment
etoposide,L01CB01,SummaryHazard 3* , 3* , 0 , 0* , Cannot be excluded
etoricoxib,M01AH05,SummaryHazard 4 , 3 , 0 , 1 , Low 
etravirine,J05AG04,SummaryHazard 6* , 3 , 0 , 3* , Insignificant
everolimus,L01XE10,SummaryHazard 8 , 3 , 3 , 2 , Insignificant 
exemestane,L02BG06,SummaryHazard - , - , - , - , Cannot be excluded 
exenatide,A10BX04,SummaryHazard - , - , - , - , Exempt
ezetimibe,C10AX09,Summary, Ezetimibe is slowly degraded in the environment, Ezetimibe has low potential for bioaccumulation, Ezetimibe has high chronic toxicity, See the report from Goodpoint 2019. This summary information about hazard comes from Fass. For the risk see the report from Goopoint 2019
famciclovir,J05AB09,SummaryHazard 3 , 3 , 0 , 0 , Insignificant
febuxostat,M04AA03,Summary," It cannot be excluded that febuxostat is persistent, due to the lack of data"," It cannot be excluded that febuxostat bioaccumulates, due to the lack of data"," It cannot be excluded that febuxostat is toxic, due to the lack of data", 
felbamate,N03AX10,SummaryHazard 4* , 3 , 0 , 1* , Cannot be excluded
felodipine,C08CA02,"SummaryThis summary information about persistence, bioaccumulation och toxicity comes from Fass. The risk comes from the reports by Goodpoint. ", Felodipine is potentially persistent, Felodipine has low potential for bioaccumulation, Felodipine has very high acute toxicity, See below reports by Goodpoint. Suggestions on how to reduce emissions of felodipine
fenofibrate,C10AB05,SummaryEnvironmental information is missing for fenofibrate on fass.se (2021-04-15). It is voluntary for manufacturers to provide information about environmental impact on fass.se. This summary information on toxicity and persistence is based on previous environmental information on fass.se for Lipanthyl (fenofibrat) from Abbott (downloaded 2013-06-25). Bioaccumulation and risk come from the report from Goodpoint. , Fenofibrate is slowly degraded in the environment," All fibrates examined are fat soluble with a log P between 3.9 and 5.2. This is likely low enough for some to be found in soluble form in surface water, but at the same time high enough to bioconcentrate effectively", Fenofibrate has low chronic toxicity," The use of bezafibrate, fenofibrate and gemfibrozil is not considered to pose an environmental risk"
fentanyl,N02AB03,SummaryHazard 4 , 3 , 0 , 1 , Cannot be excluded 
fesoterodine,G04BD11,SummaryHazard 0 , 0 , 0 , 0 , Insignificant
fexofenadine,R06AX26,SummaryHazard 3 , 3 , 0 , 0 , See below 
filgrastim,L03AA02,SummaryHazard - , - , - , - , Exempt 
finasteride,G04CB01,Summary, Finasteride is potentially persistent, Finasteride has low potential for bioaccumulation, Finasteride has high chronic toxicity, The use of finasteride (sales data Sweden 2018) has been considered to result in insignificant environmental risk. This summary information comes from Fass
fingolimod,L04AA27,SummaryHazard 3 , 0 , 0 , 3 , Insignificant 
flecainide,C01BC04,Summary," It cannot be excluded that flecainide is persistent, due to the lack of data"," It cannot be excluded that flecainide bioaccumulates, due to the lack of data"," It cannot be excluded that flecainide is toxic, due to the lack of data", 
flucloxacillin,J01CF05,Summary," It cannot be excluded that flucloxacillin is persistent, due to the lack of data", Flucloxacillin has a low potential to bioaccumulate," It cannot be excluded that flucloxacillin is toxic, due to the lack of data", 
fluconazole,J02AC01,SummaryEnvironmental information is available on fass.se for Diflucan (2021-09-21) but with information that data is missing.It is voluntary for manufacturers to provide information on environmental impact on fass.se. Data on bioaccumulation comes from previous environmental information on fass.se. Fluconazole is monitored within the framework of EU water legislation. ," It cannot be excluded that fluconazole is persistent, due to the lack of data", Fluconazole has low potential for bioaccumulation," It cannot be excluded that fluconazole is toxic, due to the lack of data", 
fludarabine,L01BB05,SummaryHazard - , - , - , - , Cannot be excluded 
flumazenil,V03AB25,SummaryHazard 4 , 3 , 0 , 1 , Insignificant
flunitrazepam,N05CD03,SummaryHazard 4* , 3 , 0 , 1* , Cannot be excluded
fluocinoloneacetonide,C05AA10,Summary," It cannot be excluded that fluocinolone acetonide is persistent, due to the lack of data"," It cannot be excluded that fluocinolone acetonide bioaccumulates, due to the lack of data"," It cannot be excluded that fluocinolone acetonide is toxic, due to the lack of data", 
fluorescein,S01JA01,SummaryHazard - , - , 0 , - , Cannot be excluded 
fluorouracil,L01BC02,Summary," It cannot be excluded that fluorouracil is persistent, due to the lack of data", Fluorouracil has low potential for bioaccumulation," It cannot be excluded that fluorouracil is toxic, due to the lack of data", 
fluoxetine,N06AB03,"SummaryEnvironmental information about fluoxetine is missing on fass.se (2020-11-02). It is voluntary for manufacturers to provide information about environmental impact on fass.se. The data on persistence, bioaccumulation and toxicity are based on previous environmental information on Fass.se. The risk comes from the reports by Goodpoint. ", Fluoxetine is potentially persistent, Fluoxetine has low potential for bioaccumulation, Fluoxetine has very high chronic toxicity, See the reports by Goodpoint. Suggestions on how to reduce emissions of fluoxetine
flupentixol,N05AF01,"SummaryEnvironmental information about flupentixol is missing on fass.se (2020-11-02). It is voluntary for manufacturers to provide information about environmental impact on fass.se. The data on persistence, bioaccumulation and toxicity are based on previous environmental information on Fass.se. The risk comes from the report by Goodpoint. ", No data, Flupentixol has high potential for bioaccumulation, No data, See the report by Goodpoint. Suggestions on how to reduce the emissions of flupentixol
fluphenazine,N05AB02,SummaryHazard 6* , 3 , 0 , 3* , Cannot be excluded 
flutamide,L02BB01,SummaryHazard - , - , 0 , - , Cannot be excluded 
fluticasonefuroate,R01AD12,"SummaryThis summary information about persistence, bioaccumation and toxicity comes from assessment reports and Fass. The conclusion about persistence comes from the assessment reports. The risk comes from the assessment report from 2019. ", Fluticasone furoate is persistent, Fluticasone furoate has low potential for bioaccumulation, Fluticasone furoate has very high chronic toxicity, The use of fluticasone furoate has been considered to result in low environmental risk
fluvastatin,C10AA04,SummaryHazard 4 , 3 , 0 , 1 , Insignificant
fluvoxamine,N06AB08,SummaryHazard 6 , 3 , 0 , 3 , Insignificant 
folicacid,B03BB01,SummaryExempt according to fass.se.,see summary,see summary,see summary,see summary
follitropinalfa,G03GA05,"SummaryFollitropin alfa has the same structure and activity as endogenous FSH. FSH is a pituitary hormone that controls the reproductive system in both males and females. Given the characteristics above, the performance of specific studies for Environmental Risk Assessment was not requested as proteins are biodegradable in the environment. Therefore, Bemfola/Ovaleap (follitropin alfa) is not expected to pose a risk to the environment. This summary information comes from assessment reports.",see summary,see summary,see summary,see summary
follitropinbeta,G03GA06,SummaryHazard - , - , - , - , Se below
fondaparinux,B01AX05,Summary," It cannot be excluded that fondaparinux is persistent, due to the lack of data"," It cannot be excluded that fondaparinux bioaccumulates, due to the lack of data"," It cannot be excluded that fondaparinux is toxic, due to the lack of data", It is stated that fondaparinux is unlikely to result in significant risk to the environment.This summary information comes from the assessment report for Arixtra (fondaparinux sodium) and is according to the company
formoterol,R03AC13,SummaryThis summary information comes from assessment reports and Fass. , Formoterol is potentially persistent, Formoterol has low potential for bioaccumulation, Formoterol has moderate acute toxicity, The use of formoterol (sales data Sweden 2017) has been considered to result in insignificant environmental risk
fosamprenavir,J05AE07,SummaryHazard 3 , 3 , 0 , 0 , Insignificant 
fosinopril,C09AA09,SummaryHazard 4* , 3 , 0 , 1* , Insignificant 
fosphenytoin,N03AB05,SummaryHazard - , - , - , - , Cannot be excluded 
framycetin,R01AX08,SummaryHazard - , - , 0 , - , Cannot be excluded 
fulvestrant,L02BA03,SummaryHazard 3 , 0 , 0 , 3 , Low 
furosemide,C03CA01,SummaryThis summary information comes from Fass. Information on bioaccumulation and risk is supported by the report from Goodpoint. , Furosemide is potentially persistent, Furosemide has low potential for bioaccumulation, Furosemide has low acute toxicity, The use of furosemide (sales data Sweden 2018) has been considered to result in insignificant environmental risk
fusidicacid,D06AX01,Summary," It cannot be excluded that fusidic acid is persistent, due to the lack of data", Fusidic acid has low potential for bioaccumulation," It cannot be excluded that fusidic acid is toxic, due to the lack of data", 
gabapentin,N03AX12,Summary," It cannot be excluded that gabapentin is persistent, due to the lack of data", Gabapentin has low potential for bioaccumulation," It cannot be excluded that gabapentin is toxic, due to the lack of data", 
gadobutrol,V08CA09,SummaryHazard 4* , 3 , 0 , 1* , Cannot be excluded
gadodiamide,V08CA03,SummaryHazard 3 , 3 , 0 , 0 , Insignificant
gadopenteticacid,V08CA01,SummaryHazard 4 , 3 , 0 , 1 , Insignificant 
gadotericacid,V08CA02,SummaryHazard - , - , - , - , Cannot be excluded 
gadoversetamide,V08CA06,SummaryHazard - , - , - , - , Cannot be excluded 
galantamine,N06DA04,"SummaryThis summary information on persistence, biockumulation and toxicity comes from Fass. The risk comes from the Goodpoint report. ", Galantamine is potentially persistent," It cannot be excluded that galantamine bioaccumulates, due to the lack of data", Galantamine has very high acute toxicity, The environmental risk is very low for galantamine from a Swedish perspective
ganciclovir,J05AB06,SummaryHazard 3 , 3 , 0 , 0 , Insignificant
ganirelix,H01CC01,Summary," It cannot be excluded that ganirelix is persistent, due to the lack of data", Ganirelix has high potential for bioaccumulation," It cannot be excluded that ganirelix is toxic, due to the lack of data", 
gefitinib,L01XE02,SummaryHazard 5* , 3 , 0 , 2* , Insignificant 
gemcitabine,L01BC05,SummaryHazard 5 , 3 , 0 , 2 , Insignificant
gemfibrozil,C10AB04,"SummaryEnvironmental information is missing for gemfibrozil on fass.se (2021-04-15). It is voluntary for manufacturers to provide information about environmental impact on fass.se. This summary information on bioaccumulation, toxicity and risk comes from the report from Goodpoint. "," It cannot be excluded that gemfibrozil is persistent, due to the lack of data"," All fibrates examined are fat soluble with a log P between 3.9 and 5.2. This is likely low enough for some to be found in soluble form in surface water, but at the same time high enough to bioconcentrate effectively"," Ecotoxicological studies are extensive for gemfibrozil and scarce for other fibrates. However, many studies are considered to be of low quality and reliability. Available and reliable efficacy data indicate a very low risk for all investigated fibrates"," The use of bezafibrate, fenofibrate and gemfibrozil is not considered to pose an environmental risk"
gentamicin,S01AA11,SummaryHazard 6 , 3 , 0 , 3 , Cannot be excluded
ginkgobiloba,N06DX02,SummaryHazard - , - , - , - , Exempt 
glibenclamide,A10BB01,"SummaryThis summary information for glibenclamide on persistence, bioaccumulation och toxicity comes from Fass. The risk comes from the report by Goodpoint. ", Glibenclamide is potentially persistent, Glibenclamide has high potential for bioaccumulation, Glibenclamide has low chronic toxicity, See the report by Goodpoint. Suggestions on how to reduce the emissions of glibenclamide
glimepiride,A10BB12,Summary, Glimepiride is potentially persistent, Glimepiride has low potential for bioaccumulation, Glimepiride has low acute toxicity, See the report from GoodPoint. This summary information about hazard comes from Fass
glipizide,A10BB07,SummaryHazard 4* , 3* , 0 , 1* , Cannot be excluded 
glucagon,H04AA01,"SummaryThe use of amino acids, proteins and peptides is not considered to have any environmental impact. This summary information comes from Fass.",see summary,see summary,see summary,see summary
glucosamine,M01AX05,Summary," It cannot be excluded that glucosamine is persistent, due to the lack of data"," It cannot be excluded that glucosamine bioaccumulates, due to the lack of data"," It cannot be excluded that glucosamine is toxic, due to the lack of data", 
glyceryltrinitrate,C01DA02,Summary, Glyceryl trinitrate is degraded in the environment, Glyceryl trinitrate has low potential for bioaccumulation, Glyceryl trinitrate has very high acute toxicity, The use of glyceryl trinitrate (sales data Sweden 2019) has been considered to result in insignificant environmental risk. This summary information comes from Fass
glycopyrroniumbromide,A03AB02,SummaryThis summary information comes from assessment reports and Fass. , Glycopyrronium is potentially persistent, Glycopyrronium has low potential for bioaccumulation, Glycopyrronium has moderate acute toxicity, The use of glycopyrronium (sales data Sweden 2018) has been considered to result in insignificant environmental risk
golimumab,L04AB06,SummaryHazard - , - , - , - , Exempt
goserelin,L02AE03,SummaryHazard - , - , - , - , See below
granisetron,A04AA02,SummaryHazard 4 , 3 , 0 , 1 , Insignificant
guaifenesin,R05CA03,SummaryHazard - , - , 0 , - , Cannot be excluded 
haloperidol,N05AD01,"SummaryThis summary information on persistence, bioaccumulation and toxicity comes from Fass. The risk comes from the report by Goodpoint. ", The potential for persistence cannot be excluded due to lack of data, Haloperidol has the potential to bioaccumulate in aquatic organisms, Haloperidol has high acute toxicity, See the report by Goodpoint. Suggestions on how to reduce the emissions of haloperidol
heparin,B01AB01,SummaryHeparin is a polysaccharide (carbohydrate). Risk. Use of carbohydrates has been considered to result in insignificant environmental impact. This summary information comes from Fass.,see summary,see summary,see summary,see summary
hyaluronicacid,M09AX01,SummaryHazard - , - , - , - , Exempt 
hydrochlorothiazide,C03AA03,Summary, Hydrochlorothiazide is potentially persistent, Hydrochlorothiazide has low potential for bioaccumulation, Hydrochlorothiazide has low chronic toxicity, The use of hydrochlorothiazide (sales data Sweden 2019) has been considered to result in insignificant environmental risk. This summary information comes from Fass
hydrocortisone,D07AA02,"SummaryFor this summary information, data on bioaccumulation comes from the Plenadren (hydrocortisone) assessment report and risk comes from the report from Goodpoint. "," It cannot be excluded that hydrocortisone is persistent, due to the lack of data", Hydrocortisone has low potential for bioaccumulation," It cannot be excluded that hydrocortisone is toxic, due to the lack of data"," Although both exposure and efficacy data are incomplete for hydrocortisone and prednisolone, there are no strong indications of environmental risk for these two substances. On the contrary, the fish plasma model and reported levels in the environment indicate low risk"
hydromorphone,N02AA03,SummaryHazard - , - , - , - , Cannot be excluded 
hydroxocobalamin,V03AB33,SummaryHazard - , - , - , - , Exempt 
hydroxycarbamide,L01XX05,SummaryHazard 3 , 3 , 0 , 0 , Insignificant 
hydroxychloroquine,P01BA02,"SummaryHazard 5 P 3 B 0 T 2 Risk Insignificant This summary information comes from Fass, see details below. ", Hydroxychloroquine is potentially persistent, Hydroxychloroquine has low potential to bioaccumulate, Hydroxychloroquine has high chronic toxicity, The use of hydroxychloroquine (sales data Sweden 2018) gives the risk insignificant
hydroxyzine,N05BB01,SummaryHazard - , - , 0 , - , Cannot be excluded 
hypromellose,S01KA02,SummaryHazard - , - , - , - , Cannot be excluded
ibandronicacid,M05BA06,SummaryHazard 2 , 0 , 0 , 2 , Insignificant
ibuprofen,M01AE01,SummaryThis summary information comes from Fass and the risk is from the report from Goodpoint. , Ibuprofen is degraded in the environment, Ibuprofen has low potential for bioaccumulation, Ibuprofen has high chronic toxicity, See the report from Goodpoint
idarubicin,L01DB06,SummaryHazard - , - , - , - , Cannot be excluded 
ifosfamide,L01AA06,SummaryHazard 6* , 3 , 0 , 3* , Cannot be excluded 
iloprost,B01AC11,SummaryHazard 1* , 0 , 0 , 1* , Cannot be excluded
imatinib,L01XE01,SummaryHazard 5 , 3 , 0 , 2 , Insignificant
imipramine,N06AA02,SummaryHazard 9 , 3 , 3 , 3 , Cannot be excluded 
imiquimod,D06BB10,SummaryThis summary information comes from assessment report and Fass. ," It can not be excluded that imiquimod is persistent, since no data is available", Imiquimod has low potential for bioaccumulation, No data, 
indacaterol,R03AC18,"SummaryThis summary information comes from assessment reports regarding the information on bioaccumulation, and from Fass. ", Indacaterol is potentially persistent, Indacaterol has low potential for bioaccumulation," Indacaterol has low acute toxicity but see comment under ""Detailed information""", The use of indacaterol (sales data Sweden 2018) has been considered to result in insignificant environmental risk
indinavir,J05AE02,SummaryHazard 1* , 0 , 0 , 1* , Insignificant 
indometacin,M01AB01,SummaryHazard 5* , 3 , 0 , 2* , Cannot be excluded 
infliximab,L04AB02,"SummaryRisk. Use of amino acids, proteins and peptides is not considered to cause any environmental impact.  This summary information comes from Fass and corresponding information can be found in assessment reports. In the environmental information from MSD: ""Even though biomolecules are exempted from environmental risk classification it should be remembered that these molecules may be biologically active.""",see summary,see summary,see summary,see summary
iobitridol,V08AB11,SummaryHazard 3 , 3 , 0 , 0 , Insignificant 
iodixanol,V08AB09,SummaryHazard 3 , 3 , 0 , 0 , Insignificant
iohexol,V08AB02,SummaryHazard 3 , 3 , 0 , 0 , Insignificant
iomeprol,V08AB10,SummaryHazard 3 , 3 , 0 , 0 , Insignificant
iopromide,V08AB05,SummaryHazard 3 , 3 , 0 , 0 , Insignificant 
ioversol,V08AB07,SummaryHazard - , - , - , - , Cannot be excluded 
ioxaglicacid,V08AB03,SummaryHazard - , - , - , - , Cannot be excluded 
ipilimumab,L01XC11,SummaryHazard - , - , - , - , Exempt Ipilimumab is a human monoclonal antibody. 
irbesartan,C09CA04,SummaryThis summary information on persistence and toxicity comes from Fass. Information on bioaccumulation and risk comes from the report by Goodpoint. , Irbesartan is slowly degraded in the environment, Data indicate high potential for bioconcentration in biota, Irbesartan has low chronic toxicity, See the report by Goodpoint. Suggestions on how to reduce the emissions of irbesartan
irinotecan,L01XX19,SummaryHazard - , - , - , - , Cannot be excluded 
isoflurane,N01AB06,SummaryHazard - , - , - , - , Cannot be excluded 
isoniazid,J04AC01,SummaryHazard 6* , 3 , 0 , 3* , Cannot be excluded 
isosorbidemononitrate,C01DA14,Summary," It cannot be excluded that isosorbide mononitrate is persistent, due to the lack of data", Isosorbide mononitrate has low potential for bioaccumulation, Isosorbide mononitrate has moderate acute toxicity, 
isotretinoin,D10BA01,Summary, No data, No data, No data, Cannot be excluded. Environmental information for isotretinoin is not available on Fass.se (2020-10-06). It is voluntary for manufacturers to publish environmental impact information on Fass.se
isradipine,C08CA03,SummaryHazard 9 , 3 , 3 , 3 , Insignificant 
itraconazole,J02AC02,SummaryHazard 6 , 3 , 3 , 0 , Insignificant
ketamine,N01AX03,SummaryThis summary information comes from Fass. ," It cannot be excluded that ketamine is persistent, due to the lack of data"," It cannot be excluded that ketamine bioaccumulates, due to the lack of data"," It cannot be excluded that ketamine is toxic, due to the lack of data", 
ketoconazole,D01AC08,Summary, Ketoconazole is potentially persistent, Ketoconazole has high potential for bioaccumulation, Ketoconazole has very high chronic toxicity," The use of ketoconazole has been considered to result in low environmental risk. However, ketoconazole is as a potentially endocrine disruptor according to the assessment report. The data on hazard are based on previous environmental information on fass.se. Environmental information is missing (2022-06-30). It is voluntary for manufacturers to provide information about environmental impact on fass.se. The risk comes from the report by Goodpoint"
ketoprofen,M01AE03,Summary, Ketoprofen is potentially persistent, Ketoprofen has low potential for bioaccumulation, Ketoprofen has high chronic toxicity," The use of ketoprofen (sales data Sweden 2018) has been considered to result in low environmental risk. This summary information comes from Fass. According to the report from Goodoint 2016: Large margin between concentrations in the environment and the concentration that affects the environment from a Swedish perspective. However, ketoprofen appears to accumulate more in fish if exposure is effected through wastewater. The possibility is that the risk is underestimated"
ketorolac,S01BC05,SummaryHazard 4 , 3 , 0 , 1 , Insignificant
ketotifen,S01GX08,SummaryEnvironmental information on ketotifen is missing on fass.se (2021-10-15). It is voluntary for manufacturers to provide information about environmental impact on fass.se.,see summary,see summary,see summary,see summary
labetalol,C07AG01,Summary," It cannot be excluded that labetalol is persistent, due to the lack of data"," It cannot be excluded that labetalol bioaccumulates, due to the lack of data"," It cannot be excluded that labetalol is toxic, due to the lack of data", 
lactitol,A06AD12,SummaryHazard - , - , - , - , Exempt 
lactulose,A06AD11,SummaryRisk. The use of carbohydrates is not considered to cause any environmental impact. This summary information comes from Fass.,see summary,see summary,see summary,see summary
lamivudine,J05AF05,SummaryHazard 4 , 3 , 0 , 1 , Insignificant
lamotrigine,N03AX09,"SummaryThis summary information on persistence, biockumulation and toxicity comes from Fass. The risk comes from the Goodpoint report. ", Lamotrigine is potentially persistent, Lamotrigine has low potential for bioaccumulation, Lamotrigine has low chronic toxicity, See the Goopoint report
lanreotide,H01CB03,SummaryHazard - , - , - , - , See below 
lansoprazole,A02BC03,SummaryHazard 4 , 3 , 0 , 1 , Cannot be excluded 
latanoprost,S01EE01,Summary," It cannot be excluded that latanoprost is persistent, due to the lack of data", Latanoprost has low potential for bioaccumulation," It cannot be excluded that latanoprost is toxic, due to the lack of data", 
leflunomide,L04AA13,SummaryHazard 5 , 3 , 0 , 2 , Insignificant
lenograstim,L03AA10,SummaryHazard - , - , - , - , Exempt 
lercanidipine,C08CA13,Summary," It cannot be excluded that lercanidipine is persistent, due to the lack of data", Lercanidipine has high potential for bioaccumulation," It cannot be excluded that lercanidipine is toxic, due to the lack of data", 
letrozole,L02BG04,Summary, Letrozole is potentially persistent, Letrozole has low potential for bioaccumulation, Letrozole has very high chronic toxicity, The use of letrozole (sales data Sweden 2018) has been considered to result in insignificant environmental risk. This summary information comes from Fass
leuprorelin,L02AE02,SummaryHazard - , - , 0 , - , Cannot be excluded Underlying data for 
levetiracetam,N03AX14,"SummaryThis summary information on persistence, biockumulation and toxicity comes from Fass UCB Nordic. The risk comes from the Goodpoint report. ", Levetiracetam is potentially persistent, Levetiracetam has low potential for bioaccumulation, Levetiracetam has moderate acute toxicity, No obvious environmental risk from a Swedish perspective
levobupivacaine,N01BB10,SummaryHazard - , - , 0 , - , Cannot be excluded Levobupivacaine is the S(-)enantiomer of the racemate bupivacaine. Underlying data for 
levocabastine,R01AC02,SummaryThe data on hazard and risk on levocabastine are based on previous environmental information on fass.se (2011-11-23). Environmental information is missing on fass.se (2021-10-15). It is voluntary for manufacturers to provide information about environmental impact on fass.se. , Levocabastine is potentially persistent, Levocabastine has no significant bioaccumulation potential, Levocabastine has moderate acute toxicity, The use of levocabastine (sales data Sweden 2010) has been considered to result in insignificant environmental risk
levofloxacin,J01MA12,SummaryHazard - , - , 0 , - , Insignificant
levomepromazine,N05AA02,SummaryHazard 6* , 3 , 0 , 3* , Cannot be excluded
levonorgestrel,G03AD01,"SummaryThis summary information on persistence, toxicity and risk comes from Fass. The risk is also supported by the reports from Goodpoint. Information on bioaccumulation comes from the reports from Goodpoint. "," Levonorgestrel is persistent. See comment below on ""potential peristence"" under Fass environmental information"," Levonorgestrel is below the limit value for high potential to bioaccumulate, but the substance binds to Sex Hormone Binding Globulin (SHBG) and just binding to SHBG is assumed to contribute to the exceptionally high bioconcentration ability (and thus potency) observed in fish for levonorgestrel", Levonorgestrel has very high chronic toxicity, The use of levonorgestrel (sales data Sweden 2019) has been judged to entail a high risk of environmental impact. Suggestions on how to reduce the emissions of levonorgestrel
lidocaine,C05AD01,SummaryThis summary information comes from Fass. Information on bioaccumulation can also be found in the assessment report Lidocaine/Prilocaine Plethora, Lidocaine is potentially persistent, Lidocaine has low potential for bioaccumulation, Lidocaine has moderate acute toxicity, The use of lidocaine (sales data Sweden 2020) has been considered to result in insignificant environmental risk
linaclotide,A06AX04,"SummaryThis summary information comes from the assessment report. Linaclotide is a peptide. A general exemption from an environmental risk assessment is granted for peptides in guideline (EMEA/CHMP/SWP/4447/00). However, these assumptions are not true for linaclotide. See further information under the heading detailed information. ", No data, ,0.0,0.0
linagliptin,A10BH05,Summary, Linagliptin is considered to be slowly degraded in the environment, Linagliptin has low potential for bioaccumulation, Linagliptin has low chronic toxicity, The use of linagliptin (sales data Sweden 2019) has been considered to result in insignificant environmental risk. This summary information comes from Fass
linezolid,J01XX08,SummaryHazard - , - , - , - , Cannot be excluded
lipegfilgrastim,L03AA14,SummaryHazard - , - , - , - , Cannot be excluded 
liraglutide,A10BX07,"SummaryThe active substance liraglutide is a peptide and is not considered to have any environmental impact. However, Fass writes the following: Even though biomolecules, such as vaccines and hormones, are exempted they should still be regarded as biologically active. This summary information comes from assessement reports and Fass.se.",see summary,see summary,see summary,see summary
lisinopril,C09AA03,SummaryHazard 3 , 3 , 0 , 0 , Low 
lithium,N05AN01,SummaryHazard - , - , - , - , Exempt 
lixisenatide,A10BX10,SummaryHazard - , - , - , - , See below 
lomustine,L01AD02,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se (2019-04-26). It is voluntary for manufacturers to provide information about environmental impact on fass.se
loperamide,A07DA03,Summary," It cannot be excluded that loperamide is persistent, due to the lack of data"," It cannot be excluded that loperamide bioaccumulates, due to the lack of data"," It cannot be excluded that loperamide is toxic, due to the lack of data", The use of loperamide has been considered to result in low risk of environmental impact (2016). Environmental information is missing on fass.se for loperamide (2023-01-23). It is voluntary for manufacturers to provide information on environmental impact on fass.se. 
loratadine,R06AX13,SummaryHazard 5 , 3 , 0 , 2 , Low 
lorazepam,N05BA06,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se (2019-03-13). It is voluntary for manufacturers to provide information about environmental impact on fass.se
losartan,C09CA01,SummaryThis summary information on persistence and toxicity comes from Fass. Information on bioaccumulation and risk comes from the report by Goodpoint. , Losartan is potentially persistent, Losartan has high potential for bioaccumulation, Losartan has low chronic toxicity, See the report from Goodpoint
lutropinalfa,G03GA07,SummaryHazard - , - , - , - , Exempt
lymecycline,J01AA04,SummaryRisk. See the report from Goodpoint. Environmental information is missing on fass.se for lymecycline (2022-08-17). It is voluntary for manufacturers to provide information on environmental impact on fass.se. Lymphcycline is rapidly hydrolysed to active tetracycline upon absorption. See also tetracycline.,see summary,see summary,see summary,see summary
lynestrenol,G03AC02,SummaryHazard - , - , 3 , - , Cannot be excluded  Underlying data are from Fass
macitentan,C02KX04,SummaryHazard - , - , 0 , - , Cannot be excluded 
macrogol,A06AD15,Summary, Macrogol is degraded in the environment, Macrogol has low potential for bioaccumulation, Macrogol has low chronic toxicity, The use of macrogol (sales data Sweden 2018) has been considered to result in low environmental risk.This summary information comes from Fass
magnesiumchloride,A12CC01,SummaryHazard - , - , - , - , Exempt According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHM
mangafodipir,V08CA05,SummaryHazard 4 , 3 , 0 , 1 , Cannot be excluded 
maprotiline,N06AA21,SummaryHazard 6 , 3 , 0 , 3 , Cannot be excluded 
mebendazole,P02CA01,SummaryHazard 6* , 3* , 0 , 3 , Insignificant 
meclozine,R06AE05,SummaryEnvironmental information is missing on fass.se (2020-11-05). It is voluntary for manufacturers to provide information about environmental impact on fass.se. The risk comes from the report by Goodpoint. , No data, No data, No data, See the report from Goodpoint. Suggestions on how to reduce the emissions of meclozine
mefloquine,P01BC02,SummaryHazard 6 , 3 , 0 , 3 , Insignificant
megestrol,L02AB01,SummaryHazard 9 , 3 , 3 , 3 , Cannot be excluded 
melatonin,N05CH01,SummaryThis summary information comes from Fass and data on bioaccumulation also from the assessment report for Slenyto (melatonin). ," It cannot be excluded that melatonin is persistent, due to the lack of data", Melatonin has low potential for bioaccumulation," It cannot be excluded that melatonin is toxic, due to the lack of data", 
meloxicam,M01AC06,SummaryHazard 4 , 3 , 0 , 1 , Insignificant 
melperone,N05AD03,SummaryHazard - , - , - , - , Cannot be excluded Environmental information for melperone is not available on Fass.se (2019-03-13). It is voluntary for manufacturers to publish environmental impact information on Fass.se
melphalan,L01AA03,SummaryHazard 2* , 0 , 0 , 2* , Cannot be excluded 
memantine,N06DX01,SummaryThe risk comes from the Goodpoint report. , No data, No data, No data, Low environmental risk. Environmental information is missing on fass.se for memantine (2021-04-07). It is voluntary for manufacturers to provide information on environmental impact on fass.se
mepivacaine,N01BB03,SummaryHazard 4* , 3* , 0 , 1* , Cannot be excluded
mercaptopurine,L01BB02,SummaryHazard 4* , 3 , 0 , 1* , Cannot be excluded 
meropenem,J01DH02,SummaryHazard 6 , 3 , 0 , 3 , Insignificant
mesalazine,A07EC02,Summary," It cannot be excluded that mesalazine is persistent, due to the lack of data", Mesalazine has low potential for bioaccumulation," It cannot be excluded that mesalazine is toxic, due to the lack of data", 
metformin,A10BA02,Summary, Metformin is slowly degraded in the environment, Metformin has low potential for bioaccumulation, Metformin has moderate chronic toxicity," The use of metformin in Sweden has been considered to result in low environmental risk. This summary information about persistence and bioaccumulation for metformin is from the assessment report Segluromet (ertugliflozin/metformin hydrochloride) 25 January 2018, EMA/86928/2018 and Fass. Information about toxicity comes from Fass environmental information for Komboglyze. The risk comes from the report of Goodpoint. Metformin is included on the watch list of substances for Union-wide monitoring in the field of water policy pursuant to Directive 2008/105/EC of the European Parliament and of the Council"
methadone,N07BC02,SummaryHazard - , - , 0 , - , Cannot be excluded 
methenamine,J01XX05,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
methotrexate,L01BA01,Summary," It cannot be excluded that methotrexate is persistent, due to the lack of data", Methotrexate has low potential for bioaccumulation, Methotrexate has high acute toxicity, Exceptional good margin between exposure based on Swedish conditions and  and known effect level. Data as basis for B and T are from the assessment report for Jylamvo. The information about B is also supported by Fass. The risk comes from the report by Goodpoint 2016
methylaminolevulinate,L01XD03,SummaryHazard 6* , 3 , 0 , 3* , Cannot be excluded
methylergometrine,G02AB01,Summary," It cannot be excluded that methylergometrine is persistent, due to the lack of data"," It cannot be excluded that methylergometrine bioaccumulates, due to the lack of data"," It cannot be excluded that methylergometrine is toxic, due to the lack of data", 
methylphenidate,N06BA04,"SummaryThis summary information comes from various Fass texts, see under detailed information, including previously published information. ", Methylphenidate is potentially persistent, Methylphenidate has low potential for bioaccumulation, Methylphenidate has high acute toxicity, The use of methylphenidate (sales data Sweden 2019) has been considered to result in insignificant environmental risk
methylprednisolone,H02AB04,Summary," It cannot be excluded that methylprednisolone is persistent, due to the lack of data"," It cannot be excluded that methylprednisolone bioaccumulates, due to the lack of data"," It cannot be excluded that methylprednisolone is toxic, due to the lack of data", 
metoclopramide,A03FA01,Summary, Metoclopramide is potentially persistent, Metoclopramide has low potential for bioaccumulation, Metoclopramide has moderate acute toxicity, The use of metoclopramide (sales data Sweden 2019) has been considered to result in insignificant environmental risk. This summary information comes from Fass
metoprolol,C07AB02,SummaryThis summary information comes from Fass. The risk is also confirmed by the investigation from Goodpoint. , Metoprolol is potentially persistent, Metoprolol has low potential for bioaccumulation, Metoprolol has moderate acute toxicity, The use of metoprolol (sales data Sweden 2017) has been considered to result in low environmental risk
metronidazole,J01XD01,Summary, Metronidazole is potentially persistent, Metronidazole has low potential for bioaccumulation, Metronidazole has low chronic toxicity," See the report from Goodpoint 2018. This summary information about hazard comes from Fass.The information about risk is from the report from Goodpoint 2018, see below"
mianserin,N06AX03,SummaryHazard - , - , 0 , - , Cannot be excluded In Sweden mianserin has been found in low concentrations. 
miconazole,G01AF04,SummaryEnvironmental information is missing on fass.se for miconazole (2021-09-21). It is voluntary for manufacturers to provide information on environmental impact on fass.se. This summary information is based on previous environmental information on fass.se. Miconazole is monitored within the framework of EU water legislation. , Miconazole is potentially persistent, Miconazole has high potential for bioaccumulation, Miconazole has high chronic toxicity, The use of miconazole (sales data Sweden 2015) has been considered to result in low environmental risk
midazolam,N05CD08,Summary," The potential for persistence of midazolam cannot be excluded, due to lack of data", Midazolam has high potential for bioaccumulation," It cannot be excluded that midazolam is toxic, due to the lack of data", 
mifepristone,G03XB01,Summary, Mifepristone is degraded in the environment, Mifepristone has low potential for bioaccumulation, Mifepristone has very high chronic toxicity, The use of mifepristone (sales data Sweden 2020) has been considered to result in insignificant environmental risk. This summary information comes from Fass
milrinone,C01CE02,SummaryHazard 4* , 3 , 0 , 1* , Cannot be excluded 
minoxidil,D11AX01,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
mirabegron,G04BD12,SummaryHazard 0 , 0 , 0 , 0 , Insignificant 
mirtazapine,N06AX11,"SummaryThis summary information on persistence, bioaccumulation and toxicity comes from Fass. For the risk, see the report by Goodpoint. ", Mirtazapine is slowly degraded in the environment, Mirtazapine has low potential for bioaccumulation, Mirtazapine has moderate chronic toxicity, See the report by Goodpoint
misoprostol,A02BB01,Summary," It cannot be excluded that misoprostol is persistent, due to the lack of data"," It cannot be excluded that misoprostol bioaccumulates, due to the lack of data"," It cannot be excluded that misoprostol is toxic, due to the lack of data", 
mitomycin,L01DC03,SummaryHazard 6 , 3 , 0 , 3 , Cannot be excluded 
mitoxantrone,L01DB07,SummaryHazard - , - , 0 , - , Cannot be excluded Underlying data for 
mizolastine,R06AX25,SummaryHazard - , - , - , - , Cannot be excluded 
moclobemide,N06AG02,SummaryHazard 4 , 3 , 0 , 1 , Cannot be excluded Underlying data for 
modafinil,N06BA07,SummaryHazard - , - , 0 , - , Cannot be excluded 
montelukast,A10BX10,SummaryThis summary information comes from Fass. , Montelukast is potentially persistent, Montelukast has high potential for bioaccumulation, Montelukast has high chronic toxicity, The use of montelukast (sales data Sweden 2018) has been considered to result in insignificant environmental risk
morphine,N02AA01,Summary," It cannot be excluded that morphine is persistent, due to the lack of data", Morphine has low potential for bioaccumulation," It cannot be excluded that morphine is toxic, due to the lack of data", 
moxifloxacin,J01MA14,SummaryHazard 6* , 3 , 0 , 3* , Cannot be excluded 
moxonidine,C02AC05,SummaryHazard 5 , 3 , 0 , 2 , Insignificant
mupirocin,R01AX06,SummaryHazard 3* , 3* , 0 , 0* , Cannot be excluded
mycophenolicacid,L04AA06,Summary, Mycophenolic acid is slowly degraded in the environment, Mycophenolic acid has low potential for bioaccumulation, Mycophenolic acid has very high chronic toxicity, The use of mycophenolic acid (sales data Sweden 2021) has been considered to result in moderate environmental risk. This summary information comes from Fass
nabumetone,M01AX01,SummaryHazard - , - , 0 , - , Cannot be excluded
nafarelin,H01CA02,"SummaryRisk: Use of amino acids, proteins and peptides is not considered to cause any environmental impact. This summary information comes from Fass.",see summary,see summary,see summary,see summary
naloxone,V03AB15,SummaryHazard 4 , 3 , 0 , 1 , Cannot be excluded 
naltrexone,N07BB04,Summary," It cannot be excluded that naltrexone is persistent, due to the lack of data"," It cannot be excluded that naltrexone bioaccumulates, due to the lack of data"," It cannot be excluded that naltrexone is toxic, due to the lack of data", 
nandrolone,A14AB01,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
naphazoline,S01GA01,SummaryHazard 7* , 3 , 3* , 1* , Cannot be excluded 
naproxen,M01AE02,"SummaryThis summary information about persistence, bioaccumulation and toxicity comes from Fass. The risk comes from the reports by Goodpoint. ", Naproxen is slowly degraded in the environment, Naproxen has low potential for bioaccumulation, Naproxen has high chronic toxicity, The use of naproxen has been considered to result in low environmental risk (year 2019)
naratriptan,N02CC02,SummaryHazard 3 , 3 , 0 , 0 , Insignificant 
natalizumab,L04AA23,SummaryHazard - , - , - , - , Exempt 
nelarabine,L01BB07,SummaryHazard 3 , 3 , 0 , 0 , Insignificant
neostigmine,N07AA01,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
nepafenac,S01BC10,SummaryHazard - , - , 0 , - , Cannot be excluded 
netilmicin,J01GB07,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
nevirapine,J05AG01,SummaryHazard 4 , 3 , 0 , 1 , Insignificant
niclosamide,P02DA01,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
nicotine,N07BA01,SummaryHazard 3 , 0 , 0 , 3 , Low 
nifedipine,C08CA05,SummaryHazard 5* , 3 , 0 , 2* , Cannot be excluded 
nilotinib,L01XE08,SummaryHazard 6 , 3 , 0 , 3 , See below 
nintedanib,L01XE31,SummaryHazard 6 , 3 , 0 , 3 , Insignificant 
nitrazepam,N05CD02,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
nitrofurantoin,J01XE01,Summary," It cannot be excluded that nitrofurantoin is persistent, due to the lack of data", Nitrofurantoin has a low potential to bioaccumulate," It cannot be excluded that nitrofurantoin is toxic, due to the lack of data"," Nitrofurantoin is considered to have a low environmental risk, both for eukaryotes (including fish) and bacteria (including risk of selection for antibiotic resistance), even if use were to increase significantly in Sweden.This hazard summary information comes from Fass. The risk comes from the report by Goodpoint.For antibiotics in general, it is recommended that these pharmaceuticals are used as restrictively as possible without jeopardise the patient's health"
nivolumab,L01XC17,SummaryHazard - , - , - , - , Exempt
nomegestrol,G03DB04,Summary, Nomegestrol acetate is potentially persistent, Nomegestrol acetate has low potential for bioaccumulation, Nomegestrol acetate has very high chronic toxicity, The use of nomegestrol acetate (sales data Sweden 2018) has been considered to result in insignificant environmental risk. This summary information comes from Fass
norepinephrine,C01CA03,SummaryHazard - , - , 0 , - , Cannot be excluded 
norethisterone,G03DC02,SummaryThis summary information comes from Fass (Bayer). , Norethisterone is potentially persistent, Norethisterone has low potential for bioaccumulation, Norethisterone has very high chronic toxicity, The use of norethisterone (sales data Sweden 2018) has been considered to result in moderate/high environmental risk
norfloxacin,S01AE02,"SummaryAll medicinal products with norfloxacin have been withdrawn from the Swedish market. Previously, there was some risk for the selection of antibiotic resistant bacteria in wastewater treatment plants in Sweden.Studies have shown that even low concentrations of antibiotics in the environment may trigger antibiotic resistance and should therefore be taken to ensure that as little as possible end up in our environment.",see summary,see summary,see summary,see summary
nortriptyline,N06AA10,Summary," It cannot be excluded that nortriptyline is persistent, due to the lack of data"," It cannot be excluded that nortriptyline bioaccumulates, due to the lack of data"," It cannot be excluded that nortriptyline is toxic, due to the lack of data", 
noscapine,R05DA07,SummaryHazard - , - , 0 , - , Cannot be excluded
nystatin,A07AA02,Summary," It cannot be excluded that nystatin is persistent, due to the lack of data"," It cannot be excluded that nystatin bioaccumulates, due to the lack of data"," It cannot be excluded that nystatin is toxic, due to the lack of data", 
octreotide,H01CB02,SummaryHazard - , - , - , - , See below 
ofloxacin,J01MA01,"SummaryOnly Ofloxacin mibe eye drops has marketing authorisation in Sweden, but the medinal product is not currently available according to Fass.se (2022-11-16). There is no environmental information on Fass.se.Ofloxacin is included on the watch list of substances for Union-wide monitoring in the field of water policy pursuant to Directive 2008/105/EC of the European Parliament and of the Council.Ofloxacin is a racemate. One of the enantiomers is levofloxacin (S-enantiomer). Therefore, see also environmental information for levofloxacin.",see summary,see summary,see summary,see summary
olaparib,L01XX46,SummaryHazard 4* , 3 , 0 , 1* , Insignificant NO
olopatadine,S01GX09,SummaryHazard - , - , 0 , - , Cannot be excluded
omalizumab,R03DX05,SummaryHazard - , - , - , - , Exempt
omeprazole,A02BC01,SummaryThis summary information comes from Fass. The risk is supported by the report from Goodpoint. , Omeprazole is potentially persistent, Omeprazole has low potential for bioaccumulation, Esomeprazole* has moderate chronic toxicity, The use of omeprazole in Sweden has been considered to result in insignificant environmental risk (year 2019). *Esomeprazole is the S-enantiomer of the racemate omeprazole. See also esomeprazole
ondansetron,A04AA01,Summary, Ondansetron is potentially persistent, Ondansetron low potential for bioaccumulation, Ondansetron has moderate chronic toxicity, The use of ondansetron (sales data Sweden 2018) has been considered to result in insignificant environmental risk. This summary information comes from Fass
orlistat,A08AB01,SummaryHazard 8 , 3 , 3 , 2 , Insignificant 
oseltamivir,J05AH02,SummaryThis summary information comes from Fass. , Oseltamivir is potentially persistent, Oseltamivir has low potential for bioaccumulation, Oseltamivir has moderate chronic toxicity, The use of oseltamivir (sales data Sweden 2017) gives the risk insignificant
oxaliplatin,L01XA03,SummaryHazard 6* , 3 , 0 , 3* , Cannot be excluded 
oxazepam,N05BA04,SummaryThis summary information comes from Fass with the exception of risk. The information on risk comes from the report by Goodpoint. , No data, No data, No data, See the report from Goodpoint. Suggestions on how to reduce the emissions of oxazepam
oxcarbazepine,N03AF02,"SummaryThis summary information on persistence, biockumulation and toxicity comes from Fass. The risk comes from the Goodpoint report. ", Oxcarbazepine is potentially persistent, Oxcarbazepine has low potential for bioaccumulation, Oxcarbazepine has moderate acute toxicity, No obvious environmental risk from a Swedish perspective
oxybutynin,G04BD04,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
oxycodone,N02AA05,Summary," It cannot be excluded that oxycodone is persistent, due to the lack of data", Oxycodone has low potential for bioaccumulation," It cannot be excluded that oxycodone is toxic, due to the lack of data", 
oxymetazoline,S01GA04,SummaryHazard 5* , 3* , 0 , 2* , Cannot be excluded 
oxytetracycline,J01AA06,Summary," It cannot be excluded that oxytetracycline is persistent, due to the lack of data"," It cannot be excluded that oxytetracycline bioaccumulates, due to the lack of data"," It cannot be excluded that oxytetracycline is toxic, due to the lack of data", 
oxytocin,H01BB02,Summary," It cannot be excluded that oxytocin is persistent, due to the lack of data"," It cannot be excluded that oxytocin bioaccumulates, due to the lack of data"," It cannot be excluded that oxytocin is toxic, due to the lack of data", 
paclitaxel,L01CD01,SummaryHazard 6* , 0 , 3 , 3* , Cannot be excluded 
paliperidone,N05AX13,SummaryHazard 4 , 3 , 0 , 1 , Insignificant 
palonosetron,A04AA05,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
pamidronicacid,M05BA03,Summary," It cannot be excluded that pamidronic acid is persistent, due to the lack of data"," It cannot be excluded that pamidronic acid bioaccumulates, due to the lack of data"," It cannot be excluded that pamidronic acid is toxic, due to the lack of data", 
pancuronium,M03AC01,SummaryHazard - , - , 0 , - , Cannot be excluded
panitumumab,L01XC08,SummaryHazard - , - , - , - , Exempt
pantoprazole,A02BC02,SummaryHazard 4 , 3 , 0 , 1 , Insignificant 
papaverine,A03AD01,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
paracetamol,N02BE01,SummaryThis summary information on bioaccumulation and toxicity comes from Fass (Panocod). The information on persistence comes from previous environmental information in Fass (Alvedon forte). The risk comes from the report by Goodpoint. Data on bioaccumulation are also supported by the report from Goodpoint. , Paracetamol is not considered to be persistent, Paracetamol has low potential for bioaccumulation, Paracetamol has moderat chronic toxicity, The use of paracetamol has been considered to result in insignificant environmental risk
parathyroidhormone,H05AA03,SummaryHazard - , - , - , - , Exempt 
paroxetine,N06AB05,SummaryHazard 6 , 3 , 0 , 3 , See below 
pegaptanib,S01LA03,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
pegfilgrastim,L03AA13,SummaryHazard - , - , - , - , Exempt
pegvisomant,H01AX01,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se (2019-06-14). It is voluntary for manufacturers to provide information about environmental impact on fass.se
pembrolizumab,L01XC18,SummaryHazard - , - , - , - , Exempt
pemetrexed,L01BA04,SummaryHazard 1 , 0 , 0 , 1 , Insignificant 
penciclovir,D06BB06,SummaryHazard 3* , 3 , 0 , 0* , Insignificant
pentoxyverine,R05DB05,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se (datum). It is voluntary for manufacturers to provide information about environmental impact on fass.se
permethrin,P03AC04,SummaryHazard 9 , 3 , 3 , 3 , Moderate 
perphenazine,N05AB03,SummaryHazard - , - , 3 , - , Cannot be excluded
pethidine,N02AB02,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
phenoxymethylpenicillin,J01CE02,Summary," It cannot be excluded that phenoxymethylpenicillin is persistent, due to the lack of data", Phenoxymethylpenicillin has low potential for bioaccumulation," It cannot be excluded that phenoxymethylpenicillin is toxic, due to the lack of data", 
phentolamine,C04AB01,Summary," It cannot be excluded that phentolamine is persistent, due to the lack of data"," It cannot be excluded that phentolamine bioaccumulates, due to the lack of data"," It cannot be excluded that phentolamine is toxic, due to the lack of data", 
phenytoin,N03AB02,No recorded data,see summary,see summary,see summary,see summary
phytomenadione,B02BA01,No recorded data,see summary,see summary,see summary,see summary
pilocarpine,S01EB01,No recorded data,see summary,see summary,see summary,see summary
pimecrolimus,D11AH02,Summary," It cannot be excluded that pimecrolimus is persistent, due to the lack of data"," It cannot be excluded that pimecrolimus bioaccumulates, due to the lack of data"," It cannot be excluded that pimecrolimus is toxic, due to the lack of data", 
pindolol,C07AA03,No recorded data,see summary,see summary,see summary,see summary
pioglitazone,A10BG03,No recorded data,see summary,see summary,see summary,see summary
piperacillin,J01CA12,No recorded data,see summary,see summary,see summary,see summary
piroxicam,M01AC01,No recorded data,see summary,see summary,see summary,see summary
pivmecillinam,J01CA08,Summary," It cannot be excluded that pivmecillinam is persistent, due to the lack of data"," It cannot be excluded that pivmecillinam bioaccumulates, due to the lack of data"," It cannot be excluded that pivmecillinam is toxic, due to the lack of data"," Pivmecillinam is expected to have low environmental risk for aquatic organisms and low risk of resistance selection in wastewater. However, there is a risk of additive effect with other beta-lactam antibiotics.Environmental information is missing for pivmecillinam on fass.se (2022-12-19). It is voluntary for manufacturers to provide information on environmental impact on fass.se. The risk comes from a report by Goodpoint 2017.For antibiotics in general, it is recommended that these pharmaceuticals are used as restrictively as possible without jeopardise the patient's health"
pizotifen,N02CX01,SummaryHazard 9* , 3 , 3 , 3* , Cannot be excluded
podophyllotoxin,D06BB04,Summary," It cannot be excluded that podophyllotoxin is persistent, due to the lack of data"," It cannot be excluded that podophyllotoxin bioaccumulates, due to the lack of data"," It cannot be excluded that podophyllotoxin is toxic, due to the lack of data", 
polymyxinb,J01XB02,Summary," It cannot be excluded that polymyxin B is persistent, due to the lack of data"," It cannot be excluded that polymyxin B bioaccumulates, due to the lack of data"," It cannot be excluded that polymyxin B is toxic, due to the lack of data", 
posaconazole,J02AC04,SummaryHazard 5 , 3 , 0 , 2 , Insignificant 
potassiumchloride,B05XA01,SummaryRisk. The use of electrolytes is not considered to have any environmental impact. The information comes from Fass.,see summary,see summary,see summary,see summary
pramipexole,N04BC05,Summary, Pramipexole is potentially persistent, Pramipexole has low potential for bioaccumulation, Pramipexole has moderate acute toxicity, The use of pramipexole (sales data Sweden 2021) has been considered to result in insignificant environmental risk. This summary information comes from Fass
prasugrel,B01AC22,SummaryThis summary information comes from Fass. , Prasugrel is degraded in the environment, Prasugrel has low potential for bioaccumulation, Prasugrel has moderate chronic toxicity, The use of prasugrel (sales data Sweden 2016) has been considered to result in insignificant environmental risk
pravastatin,C10AA03,SummaryHazard 4 , 3 , 0 , 1 , Low 
prednisolone,H02AB06,"SummaryFor this summary information, the information on bioaccumulation comes from previous environmental information on the fass.se. Environmental information can be found on fass.se that data are missing for prednisolone from Pfizer (2021-04-20). The risk comes from the report from Goodpoint. "," It cannot be excluded that prednisolone is persistent, due to the lack of data", Prednisolone has low potential for bioaccumulation," It cannot be excluded that prednisolone is toxic, due to the lack of data"," Although both exposure and efficacy data are incomplete for hydrocortisone and prednisolone, there are no strong indications of environmental risk for these two substances. On the contrary, the fish plasma model and reported levels in the environment indicate low risk"
prednisone,H02AB07,SummaryHazard - , - , 0 , - , Cannot be excluded 
pregabalin,N03AX16,SummaryHazard 3* , 3 , 0 , 0* , Insignificant 
prilocaine,N01BB04,"SummaryThis summary information on persistence, bioaccumulation and toxicity comes from the assessment report for Lidocaine/Prilocaine Plethora and Fass. The risk comes from Fass. "," It cannot be excluded that prilocaine is persistent, due to the lack of data", Prilocaine has low potential for bioaccumulation," It cannot be excluded that prilocaine is toxic, due to the lack of data", 
probenecid,M04AB01,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
progesterone,G03DA04,Summary," It cannot be excluded that progesterone is persistent, due to the lack of data"," It cannot be excluded that progesterone bioaccumulates, due to the lack of data"," It cannot be excluded that progesterone is toxic, due to the lack of data", 
proguanil,P01BB01,SummaryHazard 6 , 3 , 0 , 3 , Insignificant 
promethazine,D04AA10,SummaryThis summary information comes from the report by Goodpoint 2017 and Fass (bioaccumulation). ," It cannot be excluded that promethazine is persistent, due to the lack of data", Promethazine has high potential for bioaccumulation," Studies on the toxicity have only been carried out on one specie (water flea shows effects on reproduction at 180 microg/L), that makes a calculation of the environmental risk becomes uncertain"," Promethazine is not as well investigated for effects, but the substance has a fat solubility that indicates high potential for bioaccumulation. However, despite investigations in many countries, including Sweden, promethazine has not been detected in wastewater. The environmental risk of promethazine is therefore considered low"
propofol,N01AX10,SummaryThe data on hazard and risk are based on previous environmental information on fass.se (2011-05-24). Environmental information is missing on fass.se (2021-12-08). It is voluntary for manufacturers to provide information about environmental impact on fass.se. , Propofol is potentially persistent, No significant bioaccumulation potential, Propofol has moderate chronic toxicity, The use of propofol (sales data Sweden 2009) has been considered to result in low environmental risk
propranolol,C07AA05,Summary, Propranolol l is degraded in the environment, Propranolol has low potential for bioaccumulation, Propranolol has very high chronic toxicity, The use of propranolol (sales data Sweden 2017) has been considered to result in insignificant environmental risk. This summary information comes from Fass. The risk is confirmed by the report from Goodpoint and the assessment report
prucalopride,A06AX05,Summary, Prucalopride is persistent, Prucalopride has low potential for bioaccumulation, Prucalopride has moderate chronic toxicity, The use of prucalopride from a European perspective has been considered to result in insignificant environmental risk.This summary information comes from assessment report for Resolor (prucalopride) 2015
pseudoephedrine,R01BA02,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
pyridostigmine,N07AA02,SummaryHazard 6* , 3* , 0 , 3 , Cannot be excluded 
pyrvinium,P02CX01,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
quetiapine,N05AH04,Summary, Quetiapine is slowly degraded in the environment, Quetiapin has low potential for bioaccumulation, Quetiapin has moderate chronic toxicity, The use of quetiapin (sales data Sweden 2021) has been considered to result in insignificant environmental risk. This summary information comes from Fass
quinagolide,G02CB04,SummaryHazard - , - , - , - , Cannot be excluded 
quinapril,C09AA06,SummaryHazard - , - , - , - , Cannot be excluded
rabeprazole,A02BC04,SummaryHazard 5* , 3* , 0 , 2 , Insignificant 
raloxifene,G03XC01,SummaryHazard 8 , 3 , 3 , 2 , Cannot be excluded 
ramipril,C09AA05,"SummaryThis summary information about persistence, bioaccumulation och toxicity comes from Fass. For the risk, see the report by Goodpoint. ", Ramipril is potentially persistent, Ramipril has low potential for bioaccumulation, Ramipril has low acute toxicity," Although the environmental risk is highest for ramipril (comparative environmental risk assessment using enalapril, ramipril, lisinopril and captopril from a Swedish perspective), the overall evidence for environmental risk is still low"
ramucirumab,L01XC21,SummaryHazard - , - , - , - , Exempt
ranibizumab,S01LA04,SummaryHazard - , - , - , - , Exempt
ranitidine,A02BA02,SummaryHazard 4 , 3 , 0 , 1 , Insignificant 
rasagiline,N04BD02,SummaryHazard - , - , - , 3* , Cannot be excluded 
rasburicase,V03AF07,SummaryHazard - , - , - , - , Exempt
reboxetine,N06AX18,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
regorafenib,L01XE21,SummaryHazard 9 , 3 , 3 , 3 , See below 
remifentanil,N01AH06,SummaryThe data on hazard and risk are based on previous environmental information on fass.se (2013-08-16). Environmental information is missing on fass.se (2021-12-08). It is voluntary for manufacturers to provide information about environmental impact on fass.se. , Remifentanil is slowly degraded in the environment, Remifentanil has low potential for bioaccumulation, Remifentanil has moderate acute toxicity, 
repaglinide,A10BX02,Summary, Repaglinide is potentially persistent, Repaglinide has low potential for bioaccumulation," Repaglinide has low chronic toxicity. However, there is only data for one trophic level", 
retapamulin,D06AX13,SummaryHazard 5* , 3 , 0 , 2* , Cannot be excluded 
reteplase,B01AD07,SummaryHazard - , - , - , - , See below
retigabine,N03AX21,SummaryHazard 6 , 3 , 0 , 3 , Insignificant
ribavirin,J05AB04,SummaryHazard 4 , 3 , 0 , 1 , Insignificant 
rifabutin,J04AB04,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
rifaximin,A07AA11,SummaryThis summary information comes from Fass. , Rifaximin is persistent, Rifaximin has low potential for bioaccumulation, Rifaximin has very high chronic toxicity, The use of rifaximin (sales data Sweden 2018) has been considered to result in low environmental risk
riluzole,N07XX02,SummaryHazard 8* , 3 , 3* , 2* , Cannot be excluded 
rimexolone,S01BA13,SummaryHazard - , - , 0 , - , Cannot be excluded
risedronicacid,M05BA07,SummaryHazard 6* , 3* , 0 , 3 , Insignificant 
risperidone,N05AX08,"SummaryThis summary information about persistence, bioaccumulation and toxicity comes from Fass. The information on risk comes from the report by Goodpoint. ", Risperidone is potentially persistent, Risperidone has low potential for bioaccumulation, Risperidone has high acute toxicity, See the report from Goodpoint. Suggestions on how to reduce the emissions of risperidone
ritonavir,J05AE03,SummaryHazard 8 P 3 B 3 T 2 Risk Insignificant This summary information comes from Fass. , Ritonavir is potentially persistent, Ritonavir has high potential for bioaccumulation, Ritonavir has a high acute toxicity, The use of ritonavir (sales data Sweden 2016) gives the risk insignificant
rituximab,L01XC02,SummaryHazard - , - , - , - , Exempt
rivaroxaban,B01AF01,Summary, Rivaroxaban is slowly degraded in the environment, Rivaroxaban has low potential for bioaccumulation, Rivaroxaban has high chronic toxicity," The use of rivaroxaban (sales data Sweden 2020) has been considered to result in insignificant environmental risk. This summary information on persistence, bioaccumaltion and toxicity comes from Fass and the assessment report for Xarelto (rivaroxaban). Information about risk comes from Fass"
rivastigmine,N06DA03,"SummaryThis summary information on persistence, biockumulation and toxicity comes from Fass. The risk comes from the Goodpoint report. "," Rivastigmine is persistent. See comment below under the heading ""Detailed information"" on potentially persistent specified in Fass", Rivastigmine has low potential for bioaccumulation, Rivastigmine has moderate chronic toxicity, The environmental risk is considered to be very low from a Swedish perspective
rizatriptan,N02CC04,SummaryHazard 4 , 3 , 0 , 1 , Insignificant
romiplostim,B02BX04,SummaryHazard - , - , - , - , Exempt
ropinirole,N04BC04,SummaryHazard 4 , 3 , 0 , 1 , Insignificant 
ropivacaine,N01BB09,SummaryThe data on hazard and risk are based on previous environmental information on fass.se. Environmental information is missing on fass.se (2021-10-27). It is voluntary for manufacturers to provide information about environmental impact on fass.se. , Ropivacaine is potentially persistent, Ropivacaine has no significant bioaccumulation potential, Ropivacaine has moderate acute toxicity, The use of ropivacaine (sales data Sweden 2009) has been considered to result in insignificant environmental risk
rosuvastatin,C10AA07,"SummaryThis summary information on persistence, bioaccumulation and toxicity comes from FaSS. The risk comes from the report by Goodpoint. ", Rosuvastatin is degraded in the environment, Rosuvastatin has low potential for bioaccumulation, Rosuvastatin has high chronic toxicity,The risk seems entirely insignificant for the highly water-soluble substance rosuvastatin
roxithromycin,J01FA06,"SummaryThis summary information about persistence, bioaccumulation and toxicity comes from Fass. The information on risk comes from the report by Goodpoint. "," No data available, hence the potential for persistence of roxithromycin cannot be excluded due to lack of data", Roxithromycin has low potential for bioaccumulation, Roxithromycin has very high acute toxicity, See the report from Goodpoint. Suggestions on how to reduce the emissions of roxithromycin
salbutamol,R03AC02,SummaryThis summary information comes from Fass. , Salbutamol is potentially persistent, Salbutamol has low potential for bioaccumulation," Salbutamol has low chronic toxicity. However, data are only available for one trophic level", 
salmeterol,R03AC12,Summary, Salmeterol is potentially persistent, Salmeterol has low potential for bioaccumulation, Salmeterol has low chronic toxicity, The use of salmeterol (sales data Sweden 2019) has been considered to result in insignificant environmental risk. This summary information comes from Fass.se
saquinavir,J05AE01,SummaryHazard 7 , 3 , 3 , 1 , Insignificant
sarilumab,L04AC14,SummaryHazard - , - , - , - , See below
saxagliptin,A10BH03,SummaryHazard 2* , 0 , 0 , 2* , Insignificant 
scopolamine,N05CM05,SummaryHazard - , - , 0 , - , Cannot be excluded 
selegiline,N04BD01,SummaryHazard - , - , 0 , - , Cannot be excluded 
semaglutide,A10BJ06,"SummaryThe active substance semaglutide is a peptide and is not considered to have any environmental impact. However, Fass writes the following: Even though biomolecules, such as vaccines and hormones, are exempted they should still be regarded as biologically active. This summary information comes from assessement reports and Fass.se",see summary,see summary,see summary,see summary
sertindole,N05AE03,SummaryHazard - , - , 0 , - , Cannot be excluded 
sertraline,N06AB06,"SummaryNo new environmental information for sertraline is published on fass.se (2021-06-24). It is voluntary for manufacturers to provide information on the environmental impact on fass.se. This summary information about persistence, bioaccumulation and toxicity comes from previous Fass environmental information. The information on risk comes from the report by Goodpoint 2018. ", Sertraline is slowly degraded in the environment, Sertraline does not have the potential to accumulate in aquatic organisms, Sertraline has very high acute toxicity, See the report from Goodpoint. Suggestions on how to reduce the emissions of sertraline
sevelamer,V03AE02,Summary," It cannot be excluded that sevelamer is persistent, due to the lack of data"," It cannot be excluded that sevelamer bioaccumulates, due to the lack of data"," It cannot be excluded that sevelamer is toxic, since there is not enough data", 
sibutramine,A08AA10,SummaryHazard 6 , 3 , 0 , 3 , Cannot be excluded
sildenafil,G04BE03,Summary, Sildenafil is degraded in the environment, Sildenafil has low potential for bioaccumulation, Sildenafil has high acute toxicity, The use of sildenafil (sales data Sweden unclear) has been considered to result in insignificant environmental risk. The data on hazard and risk are based on previous environmental information on Fass.se (2011-05-12). Environmental information is missing on fass.se (2023-05-24). It is voluntary for manufacturers to provide information about environmental impact on fass.se
simvastatin,C10AA01,"SummaryThis summary information on persistence, bioaccumulation and toxicity comes from Fass. The risk comes from the report by Goodpoint. ", Simvastatin is degraded in the environment, Simvastatin has high potential for bioaccumulation, Simvastatin has very high chronic toxicity," More fat-soluble statins (simvastatin, atorvastatin) may be quite potent and (together with ezetimibe) represent a slightly higher risk than the others, but the levels in the environment are probably well below the concentrations that give rise to effects in Sweden"
sitagliptin,A10BH01,SummaryHazard 4 , 3 , 0 , 1 , Insignificant 
sodiumbicarbonate,B05XA02,SummaryRisk. The use of electrolytes is not considered to cause any environmental impact. The information comes from Fass.,see summary,see summary,see summary,see summary
sodiumchloride,B05CB01,SummaryHazard - , - , - , - , Exempt 
sodiumfluoride,A01AA01,SummaryHazard - , - , - , - , Exempt 
sodiumglycerophosphate,B05XA14,SummaryHazard - , - , - , - , Exempt According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHM
sodiumpicosulfate,A06AB08,SummaryRisk. The use of electrolytes is not considered to cause any environmental impact.The data on risk are based on previous environmental information on fass.se. Environmental information is missing (2023-01-23). It is voluntary for manufacturers to provide information about environmental impact on fass.se.,see summary,see summary,see summary,see summary
solifenacin,G04BD08,SummaryEnvironmental information is missing on fass.se for solifenacin (2021-09-21). It is voluntary for manufacturers to provide information on environmental impact on fass.se. ," It cannot be excluded that solifenacin is persistent, due to the lack of data"," It cannot be excluded that solifenacin bioaccumulates, due to the lack of data"," It cannot be excluded that solifenacin is toxic, due to the lack of data", 
somatropin,H01AC01,SummaryHazard - , - , - , - , Exempt
sorafenib,L01XE05,SummaryHazard 9 , 3 , 3 , 3 , See below 
sorbitol,A06AD18,SummaryHazard - , - , - , - , Exempt 
sotalol,C07AA07,SummaryEnvironmental information is missing on fass.se for sotalol (2021-11-12). It is voluntary for manufacturers to provide information on environmental impact on fass.se. ," It cannot be excluded that sotalol is persistent, due to the lack of data"," It cannot be excluded that sotalol bioaccumulates, due to the lack of data"," It cannot be excluded that sotalol is toxic, due to the lack of data", 
spironolactone,C03DA01,Summary," It cannot be excluded that spironolactone is persistent, due to the lack of data"," It cannot be excluded that spironolactone bioaccumulates, due to the lack of data"," It cannot be excluded that spironolactone is toxic, due to the lack of data", 
streptokinase,B01AD01,SummaryHazard - , - , - , - , Exempt 
sufentanil,N01AH03,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
sugammadex,V03AB35,SummaryHazard 4* , 3 , 0 , 1* , Insignificant
sulfasalazine,A07EC01,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
sulindac,M01AB02,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
sumatriptan,N02CC01,Summary, Sumatriptan is potentially persistent, Sumatriptan has low potential for bioaccumulation, Sumatriptan has low chronic toxicity, The use of sumatriptan (sales data Sweden 2019) has been considered to result in insignificant environmental risk. This summary information comes from Fass
sunitinib,L01XE04,SummaryHazard 6* , 3* , 0 , 3 , Insignificant
suxamethonium,M03AB01,SummaryThis summary information comes from Fass. ," It cannot be excluded that suxamethonium is persistent, due to the lack of data", Suxamethonium has low potential for bioaccumulation," It cannot be excluded that suxamethonium is toxic, due to the lack of data", 
tacrolimus,L04AD02,SummaryThis summary information comes from Fass. ," The potential for persistence of tacrolimus cannot be excluded, due to lack of data"," It annot be excluded that tacrolimus may bioaccumulate, due to lack of data", No data, 
tadalafil,G04BE08,Summary, Tadalafil is slowly degraded in the environment, Tadalafil has low potential for bioaccumulation, Tadalafil has moderate chronic toxicity," The use of tadalafil (sales data Sweden 2020) has been considered to result in insignificant environmental risk. This summary information on persistence, bioaccumulation and toxicity comes from the assessment report and Fass. The risk comes from Fass"
tafluprost,S01EE05,Summary, No data, No data, No data, Cannot be excluded. Environmental information is missing on fass.se for tafluprost (2020-09-07). It is voluntary for manufacturers to provide information on environmental impact on fass.se
tamoxifen,L02BA01,Summary," It cannot be excluded that tamoxifen is persistent, due to the lack of data"," It cannot be excluded that tamoxifen bioaccumulates, due to the lack of data"," It cannot be excluded that tamoxifen is toxic, due to the lack of data", 
tapentadol,N02AX06,SummaryHazard 4 , 3 , 0 , 1 , Insignificant 
tasonermin,L03AX11,SummaryHazard - , - , - , - , Exempt
teicoplanin,J01XA02,SummaryHazard - , - , 0 , - , Cannot be excluded 
telaprevir,J05AE11,SummaryHazard 6* , 3 , 0 , 3* , Insignificant
telithromycin,J01FA15,SummaryHazard 6* , 3 , 0 , 3* , Insignificant 
telmisartan,C09CA07,SummaryHazard 4 , 3 , 0 , 1 , See below 
temozolomide,L01AX03,SummaryHazard 1 , 0 , 0 , 1 , Insignificant 
tenecteplase,B01AD11,SummaryHazard - , - , - , - , Exempt
tenoxicam,M01AC02,SummaryThis summary information comes from Fass. ," The potential for persistence of tenoxicam cannot be excluded, due to lack of data", Tenoxicam has low potential for bioaccumulation, No data, 
terazosin,G04CA03,SummaryHazard 6* , 3 , 0 , 3* , Cannot be excluded 
terbinafine,D01BA02,Summary, Terbinafine is degraded in the environment, Terbinafine has high potential for bioaccumulation, Terbinafine has very high chronic toxicity, The use of terbinafine (sales data Sweden 2020) has been considered to result in low environmental risk. This summary information comes from Fass
terbutaline,R03AC03,SummaryHazard 3 , 3 , 0 , 0 , See below 
teriflunomide,L04AA31,SummaryHazard 4 , 3 , 0 , 1 , Insignificant 
teriparatide,H05AA02,SummaryHazard - , - , - , - , See below
terlipressin,H01BA04,SummaryHazard - , - , - , - , See below
testosterone,G03BA03,Summary, Testosterone is slowly degraded in the environment, Testosterone has high potential for bioaccumulation, Testosterone has very high acute toxicity, 
tetracycline,J01AA07,"SummaryEnvironmental information on tetracycline is not available on fass.se (2020-11-15). It is voluntary for manufacturers to publish environmental impact information on fass.se. The data on persistence, bioaccumulation and toxicity are based on previous environmental information on fass.se. The information on risk comes from the reports by Goodpoint. ", Tetracycline is potentially persistent, Tetracycline has low potential for bioaccumulation, Tetracycline has very high acute toxicity, See the reports from Goodpoint. Suggestions on how to reduce emissions of tetracycline
theophylline,R03DA04,SummaryHazard - , - , 0 , - , Cannot be excluded 
thiamazole,H03BB02,Summary," It cannot be excluded that thiamazole is persistent, due to the lack of data"," It cannot be excluded that thiamazole bioaccumulates, due to the lack of data"," It cannot be excluded that thiamazole is toxic, due to the lack of data", 
thiethylperazine,R06AD03,SummaryHazard 6 , 3 , 0 , 3 , Insignificant
thiopental,N01AF03,SummaryHazard - , - , - , - , Cannot be excluded Manufacturer has on fass.se stated that data about environmental impact is missing for the substance. It is voluntary for manufacturers to provide information on the environmental impact on fass.se
tibolone,G03CX01,SummaryThis summary information comes from Fass. ," It cannot be excluded that tibolone is persistent, due to the lack of data", Tibolone has low potential for bioaccumulation," It cannot be excluded that tibolone is toxic, due to the lack of data", 
ticagrelor,B01AC24,Summary, Ticagrelor is not considered to be persistent, Ticagrelor has low potential for bioaccumulation, Ticagrelor has moderate chronic toxicity, The use of ticagrelor (sales data Sweden 2017) has been considered to result in insignificant environmental risk. This summary information about hazard comes from the assessment report for Brilique (ticagrelor) from 2015 and fass.se for Brilique downloaded 2019-10-21. Environmental information is missing on fass.se for ticagrelor (2022-04-26). It is voluntary for manufacturers to provide information on environmental impact on fass.se
ticlopidine,B01AC05,SummaryHazard 6* , 3* , 0 , 3 , Cannot be excluded
timolol,C07AA06,SummaryThis summary information comes from Fass. ," The potential for persistence of timolol cannot be excluded, due to lack of data", Timolol has low potential for bioaccumulation, No data, 
tinidazole,P01AB02,SummaryHazard - , - , - , - , Cannot be excluded Manufacturer has on fass.se stated that data about environmental impact is missing for the substance. It is voluntary for manufacturers to provide information on the environmental impact on fass.se
tinzaparin,B01AB10,SummaryThe use of carbohydrates is not considered to have any environmental impact. This summary information comes from Fass.,see summary,see summary,see summary,see summary
tioguanine,L01BB03,SummaryHazard 6 , 3 , 0 , 3 , Cannot be excluded 
tiotropiumbromide,R03BB04,"SummaryUnderlying data for P, B and risk are from Fass's environmental information downloaded 2022-01-18. The T value comes from Fass's environmental information downloaded 2011-04-14. ", Tiotropium bromide is potentially persistent, Tiotropium bromide has low potential for bioaccumulation, Tiotropium bromide has moderate acute toxicity, 
tipranavir,J05AE09,SummaryHazard 5 , 3 , 0 , 2 , Insignificant
tirofiban,B01AC17,SummaryHazard 3 , 3 , 0 , 0 , Insignificant 
tobramycin,J01GB01,SummaryHazard 6 , 3 , 0 , 3 , Insignificant 
tocilizumab,L04AC07,SummaryHazard - , - , - , - , Exempt
tofacitinib,L04AA29,SummaryHazard 5* , 3 , 0 , 2* ," See below According to EMA's assessment report, EMA / CHM"
tolcapone,N04BX01,SummaryHazard - , - , - , - , Cannot be excluded Manufacturer has on fass.se stated that data about environmental impact is missing for the substance. It is voluntary for manufacturers to provide information on the environmental impact on fass.se
tolterodine,G04BD07,SummaryEnvironmental information is missing on fass.se for tolterodine (2021-09-21). It is voluntary for manufacturers to provide information on environmental impact on fass.se. ," It cannot be excluded that tolterodine is persistent, due to the lack of data"," It cannot be excluded that tolterodine bioaccumulates, due to the lack of data"," It cannot be excluded that tolterodine is toxic, due to the lack of data", 
topiramate,N03AX11,"SummaryThis summary information on persistence, biockumulation and toxicity comes from Fass. The risk comes from the Goodpoint report. "," It cannot be excluded that topiramate is persistent, due to the lack of data", Topiramate has low potential for bioaccumulation, Topiramate has moderate acute toxicity, No obvious environmental risk from a Swedish perspective
topotecan,L01XX17,SummaryHazard 1* , 0 , 0 , 1* , Cannot be excluded 
torasemide,C03CA04,SummaryHazard 4 , 3 , 0 , 1 , Insignificant
trabectedin,L01CX01,SummaryHazard - , - , - , - , Cannot be excluded Manufacturer has on fass.se stated that data about environmental impact is missing for the substance. It is voluntary for manufacturers to provide information on the environmental impact on fass.se
tramadol,N02AX02,SummaryHazard - , - , - , - , See below Environmental information for the substance is not available on Fass.se (2019-02-15). It is voluntary for manufacturers to publish environmental impact information on Fass.se
trandolapril,C09AA10,SummaryHazard 6* , 3 , 0 , 3* , Insignificant
tranexamicacid,B02AA02,"SummaryThe use of amino acids, proteins and peptides is not considered to have any environmental impact. This summary information comes from Fass.",see summary,see summary,see summary,see summary
trastuzumab,L01XC03,SummaryHazard - , - , - , - , Exempt 
travoprost,S01EE04,"SummaryThis summary information is from the SPC (Summary of Product Characteristics) for Izba (travoprost) section 5.3 (downloaded 2020-09-08). ""Travoprost is considered a persistent, bioaccumulative and toxic (PBT) substance. Hence, despite the very small amounts of travoprost used by patients in eye drops, a risk to the environment cannot be excluded.""",see summary,see summary,see summary,see summary
tretinoin,D10AD01,SummaryHazard - , - , - , - , Cannot be excluded Manufacturer has on fass.se stated that data about environmental impact is missing for the substance. It is voluntary for manufacturers to provide information on the environmental impact on fass.se
triazolam,N05CD05,SummaryHazard - , - , - , - , Cannot be excluded Manufacturer has on fass.se stated that data about environmental impact is missing for the substance. It is voluntary for manufacturers to provide information on the environmental impact on fass.se
trihexyphenidyl,N04AA01,SummaryHazard - , - , - , - , Cannot be excluded Manufacturer has on fass.se stated that data about environmental impact is missing for the substance. It is voluntary for manufacturers to provide information on the environmental impact on fass.se
trimethoprim,J01EA01,"SummaryThe data on persistence, bioaccumulation and toxicity for trimethoprim are from fass.se. The information on risk comes from the reports by Goodpoint. Trimethoprim is monitored within the framework of EU water legislation.  ", Trimethoprim is potentially persistent, Trimethoprim has low potential for bioaccumulation, Trimethoprim has moderate chronic toxicity, See the reports from Goodpoint. Suggestions on how to reduce emissions of trimethoprim
trimipramine,N06AA06,SummaryHazard 6 , 3 , 0 , 3 , Cannot be excluded 
triptorelin,L02AE04,SummaryHazard - , - , - , - , See below
tropicamide,S01FA06,SummaryHazard - , - , 0 , - , Cannot be excluded 
tropisetron,A04AA03,SummaryHazard 6* , 3 , 3* , 3 , Cannot be excluded 
ulipristal,G03AD02,SummaryThe data on hazard and risk are based on previous environmental information on fass.se. Environmental information is missing (2022-04-11). It is voluntary for manufacturers to provide information about environmental impact on fass.se. ," It cannot be excluded that ulipristal is persistent, due to the lack of data", Ulipristal has the potential to be stored in aquatic organisms," It cannot be excluded that ulipristal is toxic, due to the lack of data", 
urofollitropin,G03GA04,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se (2019-06-14). It is voluntary for manufacturers to provide information about environmental impact on fass.se
ursodeoxycholicacid,A05AA02,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
ustekinumab,L04AC05,SummaryHazard - , - , - , - , Exempt 
valaciclovir,J05AB11,Summary, Valaciclovir is potentially persistent, Valaciclovir has low potential for bioaccumulation, Valaciclovir has low chronic toxicity, The use of valaciclovir (sales data Sweden 2019) has been considered to result in insignificant environmental risk. This summary information comes from Fass
valganciclovir,J05AB14,SummaryHazard 3 , 3 , 0 , 0 , Insignificant 
valproicacid,N03AG01,Summary, Valproic acid is potentially persistent, Valproic acid has low potential for bioaccumulation, Valproic acid has low chronic toxicity, The use of valproic acid (sales data Sweden 2019) has been considered to result in insignificant environmental risk. This summary information comes from Fass
valsartan,C09CA03,SummaryThis summary information comes from the report from Goodpoint. , Valsartan is potentially persistent, Valsartan has high potential for bioaccumulation, Valsartan has low chronic toxicity, See the report from Goodpoint
vardenafil,G04BE09,SummaryHazard 6* , 3 , 0 , 3* , Cannot be excluded 
varenicline,N07BA03,Summary, Varenicline is slowly degrade in the environment, Varenicline has low potential for bioaccumulation, Varenicline has very high chronic toxicity, The use of varenicline (sales data Sweden 2020) has been considered to result in nsignificant environmental risk.This summary information comes from Fass
vecuronium,M03AC03,SummaryHazard - , - , 0 , - , Cannot be excluded 
vedolizumab,L04AA33,SummaryHazard - , - , - , - , Exempt
venlafaxine,N06AX16,SummaryThe data on hazard are based on previous environmental information on fass.se. Environmental information is missing (2021-09-10). It is voluntary for manufacturers to provide information about environmental impact on fass.se. The information on risk comes from the reports by Goodpoint. Venlafaxine is monitored within the framework of EU water legislation. , Venlafaxine is slowly degraded in the environment, Venlafaxine does not have the potential to accumulate in aquatic organisms, Venlafaxine has high acute toxicity, See the reports from Goodpoint. Suggestions on how to reduce emissions of venlafaxine
verapamil,C08DA01,Summary," It cannot be excluded that verapamil is persistent, due to the lack of data", Verapamil has low potential for bioaccumulation, Verapamil has moderate acute toxicity, 
vernakalant,C01BG11,SummaryHazard - , - , 0 , - , Cannot be excluded 
verteporfin,S01LA01,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
vigabatrin,N03AG04,SummaryHazard 4* , 3* , 0 , 1* , Cannot be excluded 
vildagliptin,A10BH02,SummaryHazard 4* , 3 , 0 , 1* , Insignificant 
vinblastine,L01CA01,SummaryHazard - , - , - , - , Cannot be excluded 
vincristine,L01CA02,SummaryHazard - , - , - , - , Cannot be excluded 
vindesine,L01CA03,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
vinorelbine,L01CA04,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
voriconazole,J02AC03,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
vortioxetine,N06AX26,SummaryHazard 9 , 3 , 3 , 3 , See below 
warfarin,B01AA03,Summary, Warfarin is potentially persistent, Warfarin has low potential for bioaccumulation, Warfarin has moderate acute toxicity, The use of warfarin (sales data Sweden 2010) has been considered to result in insignificant environmental risk.The data on hazard and risk are based on previous environmental information on fass.se. Environmental information is missing (2022-06-17). It is voluntary for manufacturers to provide information about environmental impact on fass.se
xylometazoline,R01AA07,SummaryHazard 7* , 3 , 3 , 1* , Cannot be excluded 
zaleplon,N05CF03,SummaryHazard - , - , - , - , Cannot be excluded Environmental information is missing on fass.se. It is voluntary for manufacturers to provide information about environmental impact on fass.se
zidovudine,J05AF01,SummaryHazard 4* , 3 , 0 , 1* , Cannot be excluded 
zoledronicacid,M05BA08,Summary," It cannot be excluded that zoledronic acid is persistent, due to the lack of data"," It cannot be excluded that zoledronic acid bioaccumulates, due to the lack of data"," It cannot be excluded that zoledronic acid is toxic, due to the lack of data", 
zolmitriptan,N02CC03,Summary, Zolmitriptan is degraded in the environment, Zolmitriptan has low potential for bioaccumulation, Zolmitriptan has moderate chronic toxicity, The use of zolmitriptan (sales data Sweden 2019) has been considered to result in insignificant environmental risk. This summary information comes from Fass
zolpidem,N05CF02,"SummaryThis summary information on persistence, bioaccumulation and toxicity comes from Fass. The risk comes from the report from Goodpoint. ", Zolpidem is potentially persistent, Zolpidem has low potential for bioaccumulation, Zolpidem has moderate chronic toxicity," Zolpidem is poorly investigated, but existing data indicate low environmental risk"
zonisamide,N03AX15,"SummaryEnvironmental information is missing on fass.se (2021-04-14). It is voluntary for manufacturers to provide information about environmental impact on fass.se. Informaton on bioaccumulation, toxicity and risk comes from the Goodpoint report. "," It cannot be excluded that zonisamide is persistent, due to the lack of data", Log P values strongly contradict any significant bioconcentration in biota, All available aquatic ecotoxicological studies indicate a very low toxicity, No obvious environmental risk from a Swedish perspective
zopiclone,N05CF01,"SummaryThis summary information on persistence, bioaccumulation and toxicity comes from Fass. The risk comes from the report by Goodpoint "," It cannot be excluded that zopiclone is persistent, due to the lack of data", Zopiclone has low potential for bioaccumulation," It cannot be excluded that zopiclone is toxic, due to the lack of data", See the report by Goodpoint
zuclopenthixol,N05AF05,SummaryHazard - , - , 3 , - , Cannot be excluded 
